<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523419310372</prism:url><dc:identifier>doi:10.1016/j.ejmech.2019.111885</dc:identifier><eid>1-s2.0-S0223523419310372</eid><prism:doi>10.1016/j.ejmech.2019.111885</prism:doi><pii>S0223-5234(19)31037-2</pii><dc:title>NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>186</prism:volume><prism:startingPage>111885</prism:startingpage><prism:pageRange>111885</prism:pagerange><articleNumber>111885</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-01-15</prism:coverdate><prism:coverDisplayDate>15 January 2020</prism:coverdisplaydate><prism:copyright>© 2019 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Kaoud, Tamer S.</dc:creator><dc:creator>Mohassab, Aliaa M.</dc:creator><dc:creator>Hassan, Heba A.</dc:creator><dc:creator>Yan, Chunli</dc:creator><dc:creator>Van Ravenstein, Sabrina X.</dc:creator><dc:creator>Abdelhamid, Dalia</dc:creator><dc:creator>Dalby, Kevin N.</dc:creator><dc:creator>Abdel-Aziz, Mohamed</dc:creator><dc:description>
                  Constitutive activation of STAT3 can play a vital role in the development of melanoma. STAT3-targeted therapeutics are reported to show efficacy in melanomas harboring the BRAFV600E mutant and also in vemurafenib-resistant melanomas. We designed and synthesized a series of substituted nitric oxide (NO)-releasing quinolone-1,2,4-triazole/oxime hybrids, hypothesizing that the introduction of a STAT3 binding scaffold would augment their cytotoxicity. All the hybrids tested showed a comparable level of in vitro NO production. 7b and 7c exhibited direct binding to the STAT3-SH domain with IC50 of ∼ 0.5 μM. Also, they abrogated STAT3 tyrosine phosphorylation in several cancer cell lines, including the A375 melanoma cell line that carries the BRAFV600E mutation. At the same time, they did not affect the phosphorylation of upstream kinases or other STAT isoforms. 7c inhibited STAT3 nuclear translocation in mouse embryonic fibroblast while 7b and 7c inhibited STAT3 DNA-binding activity in the A375 cell line. Their anti-proliferating activity is attributed to their ability to trigger the production of reactive oxygen species and induce G1 cell cycle arrest in the A375 cell line. Interestingly, 7b and 7c showed robust cell growth suppression and apoptosis induction in two pairs of BRAF inhibitor-naïve (-S) and resistant (-R) melanoma cell lines containing a BRAF V600E mutation. Surprisingly, MEL1617-R cells that are known to be more resistance to MEK inhibition by GSK1120212 than MEL1617-S cells exhibit a similar response to 7b and 7c.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Quinolines</dcterms:subject><dcterms:subject>Triazoles</dcterms:subject><dcterms:subject>STAT3</dcterms:subject><dcterms:subject>NO donors</dcterms:subject><dcterms:subject>Melanoma</dcterms:subject><dcterms:subject>Acquired resistance to BRAF-Inhibition</dcterms:subject><dcterms:subject>BRAF V600E mutant</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523419310372" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523419310372" rel="scidir"/></link></coredata><objects><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="202" height="164" size="4783">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="9631">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="129" height="164" size="9994">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="131" height="164" size="6427">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="107" size="6153">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="152" height="163" size="11782">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="190" height="164" size="13502">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="130" height="163" size="7656">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="116" height="164" size="7299">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="164" size="10312">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="540" size="62883">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="714" height="684" size="107494">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="680" size="90229">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="522" height="653" size="70574">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="409" height="200" size="24530">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="623" size="119039">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="462" size="69966">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="534" height="671" size="57909">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="755" size="97606">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="540" size="72103">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="2391" size="493921">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3161" height="3026" size="815493">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2369" height="3013" size="800846">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2313" height="2895" size="571426">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1810" height="886" size="196422">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2567" height="2759" size="1491992">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2369" height="2046" size="675033">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2367" height="2974" size="585663">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="3344" size="793634">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2368" height="2392" size="636209">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="4182334">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-mmc1.pdf?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="2958242">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310372-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85075869378</scopus-id><scopus-eid>2-s2.0-85075869378</scopus-eid><pubmed-id>31784187</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85075869378" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20191114">2019-11-14</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20191114">2019-11-14</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20191228">2019-12-28</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20191228">2019-12-28</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2019-12-28T16:45:49</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523419310372</xocs:eid>
      <xocs:pii-formatted>S0223-5234(19)31037-2</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523419310372</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2019.111885</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523419X00239</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20200217">2020-02-17T02:45:07.483649Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200115</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1573753656">2019-11-14T17:47:36.54981Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>186</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>186</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 186</xocs:vol-iss-suppl-text>
      <xocs:sort-order>31</xocs:sort-order>
      <xocs:first-fp>111885</xocs:first-fp>
      <xocs:article-number>111885</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>111885</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20200115</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 January 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-01-15</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2019 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>NORELEASINGSTAT3INHIBITORSSUPPRESSBRAFMUTANTMELANOMAGROWTH</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>KAOUD</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>T</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Screening of anticancer activity and SAR analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>NO-releasing hybrids</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Direct binding to the STAT3 SH2 domain</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>The designed hybrids are selective STAT3 inhibitors <ce:italic>in cancer cells</ce:italic>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Sensitivity of mutant KRAS or BRAF-expressing cells towards STAT3 inhibition by 7b</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>The mechanism of anticancer activity in the BRAF mutant A375 melanoma cell line</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>The mechanism of anticancer activity in BRAF mutant melanoma with SB-590885-acquired resistance</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of compounds <ce:bold>1a-f</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Phenylquinoline-4-carboxylic acid <ce:bold>(1a)</ce:bold> [<ce:cross-ref id="crosref0650" refid="bib44">44</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-(4-Chlorophenyl)quinoline-4-carboxylic acid <ce:bold>(1b)</ce:bold> [<ce:cross-ref id="crosref0655" refid="bib44">44</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-(4-Methoxyphenyl)quinoline-4-carboxylic acid <ce:bold>(1c)</ce:bold> [<ce:cross-ref id="crosref0660" refid="bib44">44</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-(4-Chlorophenyl)-6-methoxyquinoline-4-carboxylic acid <ce:bold>(1d)</ce:bold> [<ce:cross-ref id="crosref0665" refid="bib45">45</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-Methoxy-2-(4-methoxyphenyl)quinoline-4-carboxylic acid <ce:bold>(1e)</ce:bold> [<ce:cross-ref id="crosref0670" refid="bib45">45</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-(3,4-Dimethoxyphenyl)-6-methoxyquinoline-4-carboxylic acid <ce:bold>(1f)</ce:bold> [<ce:cross-ref id="crosref0675" refid="bib46">46</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of compounds <ce:bold>(2a-f)</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Ethyl 2-phenylquinoline-4-carboxylate <ce:bold>(2a)</ce:bold> [<ce:cross-ref id="crosref0680" refid="bib47">47</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Ethyl 2-(4-chlorophenyl)quinoline-4-carboxylate <ce:bold>(2b)</ce:bold> [<ce:cross-ref id="crosref0685" refid="bib48">48</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Ethyl 2-(4-methoxyphenyl)quinoline-4-carboxylate (2c) [<ce:cross-ref id="crosref0690" refid="bib49">49</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Ethyl 2-(4-chlorophenyl)-6-methoxyquinoline-4-carboxylate <ce:bold>(2d)</ce:bold> [<ce:cross-ref id="crosref0695" refid="bib45">45</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Ethyl 6-methoxy-2-(4-methoxyphenyl)quinoline-4-carboxylate <ce:bold>(2e)</ce:bold> [<ce:cross-ref id="crosref0700" refid="bib45">45</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Ethyl 2-(3,4-dimethoxyphenyl)-6-methoxyquinoline-4-carboxylate <ce:bold>(2f)</ce:bold> [<ce:cross-ref id="crosref0705" refid="bib50">50</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of compounds <ce:bold>(3a-f)</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Phenylquinoline-4-carbohydrazide <ce:bold>(3a)</ce:bold> [<ce:cross-ref id="crosref0710" refid="bib51">51</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-(4-Chlorophenyl)quinoline-4-carbohydrazide <ce:bold>(3b)</ce:bold> [<ce:cross-ref id="crosref0715" refid="bib52">52</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-(4-Methoxyphenyl)quinoline-4-carbohydrazide <ce:bold>(3c)</ce:bold> [<ce:cross-ref id="crosref0720" refid="bib52">52</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-(4-Chlorophenyl)-6-methoxyquinoline-4-carbohydrazide <ce:bold>(3d)</ce:bold> [<ce:cross-ref id="crosref0725" refid="bib45">45</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-Methoxy-2-(4-methoxyphenyl)quinoline-4-carbohydrazide <ce:bold>(3e)</ce:bold> [<ce:cross-ref id="crosref0730" refid="bib45">45</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-(3,4-Dimethoxyphenyl)-6-methoxyquinoline-4-carbohydrazide <ce:bold>(3f)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of compounds <ce:bold>(4a-i</ce:bold>)</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-Phenyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4a)</ce:bold> [<ce:cross-ref id="crosref0740" refid="bib54">54</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-Allyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4b)</ce:bold> [<ce:cross-ref id="crosref0745" refid="bib53">53</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-Allyl-5-(2-(4-chlorophenyl)quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4c)</ce:bold> [<ce:cross-ref id="crosref0750" refid="bib53">53</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>5-(2-(4-Chlorophenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4d)</ce:bold> [<ce:cross-ref id="crosref0755" refid="bib53">53</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>5-(2-(4-Methoxyphenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4e)</ce:bold> [<ce:cross-ref id="crosref0760" refid="bib53">53</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-Allyl-5-(2-(4-methoxyphenyl)quinolin-4-yl)-4H-1,2,4-triazole-3-thiol <ce:bold>(4f)</ce:bold> [<ce:cross-ref id="crosref0765" refid="bib53">53</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>5-(2-(4-Chlorophenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4g)</ce:bold> [<ce:cross-ref id="crosref0770" refid="bib53">53</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>5-(6-Methoxy-2-(4-methoxyphenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4h)</ce:bold> [<ce:cross-ref id="crosref0775" refid="bib53">53</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>5-(2-(3,4-Dimethoxyphenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4i)</ce:bold> [<ce:cross-ref id="crosref0780" refid="bib53">53</ce:cross-ref>]</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthesis of <ce:italic>N</ce:italic>-(4-acetylphenyl)-2-bromoacetamide <ce:bold>(</ce:bold>
                     <ce:bold>5</ce:bold>
                     <ce:bold>)</ce:bold> [<ce:cross-ref id="crosref0785" refid="bib55">55</ce:cross-ref>]</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of compounds <ce:bold>(6a-i)</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((4-phenyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6a)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((4-allyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6b)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((4-allyl-5-(2-(4-chlorophenyl)-quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6c)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(2-(4-chlorophenyl)quinolin-4-yl)-4-phenyl 4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6d)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(2-(4-methoxyphenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6e)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((4-allyl-5-(2-(4-methoxyphenyl)-quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6f)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(2-(4-chlorophenyl)-6-methoxy-quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6g)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(6-methoxy-2-(4-methoxyphenyl)-quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6h)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(2-(3,4-dimethoxyphenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6i)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of compounds <ce:bold>(7a-i)</ce:bold> [<ce:cross-ref id="crosref0790" refid="bib56">56</ce:cross-ref>]</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-(1-(Hydroxyimino)ethyl)phenyl)-2-((4-phenyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(7a)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-((4-Allyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)-thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl)acetamide <ce:bold>(7b)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-((4-Allyl-5-(2-(4-chlorophenyl)quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl)acetamide <ce:bold>(7c)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-((5-(2-(4-Chlorophenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl)acetamide <ce:bold>(7d)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-(1-(Hydroxyimino)ethyl)phenyl)-2-((5-(2-(4-methoxy-phenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(7e)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-((4-Allyl-5-(2-(4-methoxyphenyl)quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl)acetamide <ce:bold>(7f)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-((5-(2-(4-Chlorophenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl) acetamide <ce:bold>(7g)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-(1-(Hydroxyimino)ethyl)phenyl)-2-((5-(6-methoxy-2-(4-methoxy phenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)- acetamide <ce:bold>(7h)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-((5-(2-(3,4-Dimethoxyphenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)- phenyl)acetamide <ce:bold>(7i)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological evaluation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgment</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>CHABNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-first-fp>633</xocs:ref-first-fp>
            <xocs:ref-last-lp>637</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>RUSSO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1481</xocs:ref-first-fp>
            <xocs:ref-last-lp>1489</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2041</xocs:ref-first-fp>
            <xocs:ref-last-lp>2049</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>FURTEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>308</xocs:ref-first-fp>
            <xocs:ref-last-lp>318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>XIONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>926</xocs:ref-first-fp>
            <xocs:ref-last-lp>957</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>WEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>241</xocs:ref-first-fp>
            <xocs:ref-last-lp>250</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>NIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>5059</xocs:ref-first-fp>
            <xocs:ref-last-lp>5063</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>KORTYLEWSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>315</xocs:ref-first-fp>
            <xocs:ref-last-lp>327</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>XIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>3550</xocs:ref-first-fp>
            <xocs:ref-last-lp>3560</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>BECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1158</xocs:ref-first-fp>
            <xocs:ref-last-lp>1166</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>CHAPMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2507</xocs:ref-first-fp>
            <xocs:ref-last-lp>2516</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>FLAHERTY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1694</xocs:ref-first-fp>
            <xocs:ref-last-lp>1703</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>FLAHERTY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>809</xocs:ref-first-fp>
            <xocs:ref-last-lp>819</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>LONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1087</xocs:ref-first-fp>
            <xocs:ref-last-lp>1095</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>NOTARANGELO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>147</xocs:ref-first-fp>
            <xocs:ref-last-lp>155</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>89</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3549</xocs:ref-first-fp>
            <xocs:ref-last-lp>3563</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>MIYOSHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>108</xocs:ref-first-fp>
            <xocs:ref-last-lp>117</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>WONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>883</xocs:ref-first-fp>
            <xocs:ref-last-lp>887</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4700</xocs:ref-first-fp>
            <xocs:ref-last-lp>4705</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>DUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>11</xocs:ref-first-fp>
            <xocs:ref-last-lp>19</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>BECERRIL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>291</xocs:ref-first-fp>
            <xocs:ref-last-lp>300</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>HOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>5948</xocs:ref-first-fp>
            <xocs:ref-last-lp>5954</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>5036</xocs:ref-first-fp>
            <xocs:ref-last-lp>5046</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>7617</xocs:ref-first-fp>
            <xocs:ref-last-lp>7635</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>507</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>MATSUNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>371</xocs:ref-first-fp>
            <xocs:ref-last-lp>375</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>BECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>145</xocs:ref-first-fp>
            <xocs:ref-last-lp>151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>TROTT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>455</xocs:ref-first-fp>
            <xocs:ref-last-lp>461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>THOMAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>18</xocs:ref-first-fp>
            <xocs:ref-last-lp>31</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1922</xocs:ref-first-fp>
            <xocs:ref-last-lp>1933</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3972</xocs:ref-first-fp>
            <xocs:ref-last-lp>3979</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2718</xocs:ref-first-fp>
            <xocs:ref-last-lp>2731</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>BARTOLOWITS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2371</xocs:ref-first-fp>
            <xocs:ref-last-lp>2378</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>752</xocs:ref-first-fp>
            <xocs:ref-last-lp>764</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>543</xocs:ref-first-fp>
            <xocs:ref-last-lp>554</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>887</xocs:ref-first-fp>
            <xocs:ref-last-lp>897</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>GOUGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2252</xocs:ref-first-fp>
            <xocs:ref-last-lp>2261</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>TIMOFEEVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>799</xocs:ref-first-fp>
            <xocs:ref-last-lp>809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>WATSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1987</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>8</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>XIONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>287</xocs:ref-first-fp>
            <xocs:ref-last-lp>297</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>207</xocs:ref-first-fp>
            <xocs:ref-last-lp>221</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>KAOUD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5232</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>MUSCIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>611</xocs:ref-first-fp>
            <xocs:ref-last-lp>614</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>ELFEKY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>104</xocs:ref-first-fp>
            <xocs:ref-last-lp>116</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>TRIKOJUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1932</xocs:ref-pub-year>
            <xocs:ref-first-fp>273</xocs:ref-first-fp>
            <xocs:ref-last-lp>278</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>267</xocs:ref-first-fp>
            <xocs:ref-last-lp>273</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>LEARDINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1984</xocs:ref-pub-year>
            <xocs:ref-first-fp>1320</xocs:ref-first-fp>
            <xocs:ref-last-lp>1321</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>ZEMTSOVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>267</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>RAULFS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1990</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2193</xocs:ref-first-fp>
            <xocs:ref-last-lp>2202</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>METWALLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>8675</xocs:ref-first-fp>
            <xocs:ref-last-lp>8682</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>MOHASSAB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>242</xocs:ref-first-fp>
            <xocs:ref-last-lp>259</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>ELAAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>90</xocs:ref-first-fp>
            <xocs:ref-last-lp>99</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>XIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>4898</xocs:ref-first-fp>
            <xocs:ref-last-lp>4908</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>ABDELLAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>63</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>KAOUD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>721</xocs:ref-first-fp>
            <xocs:ref-last-lp>725</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>276</xocs:ref-first-fp>
            <xocs:ref-last-lp>284</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>SANCISI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1868</xocs:ref-first-fp>
            <xocs:ref-last-lp>1882</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>MORRIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2785</xocs:ref-first-fp>
            <xocs:ref-last-lp>2791</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>DOLINSKY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>W665</xocs:ref-first-fp>
            <xocs:ref-last-lp>W667</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>BAKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>10037</xocs:ref-first-fp>
            <xocs:ref-last-lp>10041</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>PETTERSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1605</xocs:ref-first-fp>
            <xocs:ref-last-lp>1612</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>KAOUDX2020X111885</xocs:refkey3>
         <xocs:refkey4ai>KAOUDX2020X111885XT</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2021-12-28T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2021-12-28T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2019 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2019-11-21T06:25:25.454Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency>Graduate School, University of Texas, Austin</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100005688</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6252001</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(19)31037-2</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523419310372</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523419310372</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2019.111885</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2020-02-17T02:45:07.483649Z</xocs:timestamp>
         <xocs:cover-date-start>2020-01-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/MAIN/application/pdf/635eb13ad937d46445ce5f55b9d3f15e/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>3731071</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>19</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523419310372-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/PREVIEW/image/png/9b82c48fdd44c4e40ec34e9e21d4edcf/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>55893</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/sc1/THUMBNAIL/image/gif/a3da3d020becefd8bdbb248e2e52e57a/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4783</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>202</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr6/THUMBNAIL/image/gif/8f98dbd2b1c934d5d7cf8bae8d5b525b/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9631</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr2/THUMBNAIL/image/gif/588cec3fa8294263493135eca0a870ba/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9994</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>129</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr1/THUMBNAIL/image/gif/5c885c564bdf18032644ff04f12aab30/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6427</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>131</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/fx1/THUMBNAIL/image/gif/a5de6b1c09abd038e157eed354e0464f/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6153</xocs:filesize>
               <xocs:pixel-height>107</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr7/THUMBNAIL/image/gif/d7e515b6c0bab2a839ebf3f4e5a92f72/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11782</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>152</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr3/THUMBNAIL/image/gif/f2652dbc6625e5e2cccac55d95a68e8a/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13502</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>190</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr4/THUMBNAIL/image/gif/50062f22b28b9fa1de6a49ff165b68b9/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7656</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>130</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr8/THUMBNAIL/image/gif/4b0d68b46894ec4a53f8328593e543eb/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7299</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>116</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr5/THUMBNAIL/image/gif/b4bf06b222c4bb3ab7895e6eeeb710eb/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10312</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/sc1/DOWNSAMPLED/image/jpeg/434754863ecf8fe16cbea3da602492e5/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>62883</xocs:filesize>
               <xocs:pixel-height>540</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr6/DOWNSAMPLED/image/jpeg/fddfc1971f49c1a30fe76aa4379d882c/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>107494</xocs:filesize>
               <xocs:pixel-height>684</xocs:pixel-height>
               <xocs:pixel-width>714</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr2/DOWNSAMPLED/image/jpeg/b3c95714984ed964975a74dba59a145c/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>90229</xocs:filesize>
               <xocs:pixel-height>680</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr1/DOWNSAMPLED/image/jpeg/fb0e6d78b688eedc3a32d27474b405b2/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>70574</xocs:filesize>
               <xocs:pixel-height>653</xocs:pixel-height>
               <xocs:pixel-width>522</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/fx1/DOWNSAMPLED/image/jpeg/0c1315f683f65c9ae51c4b482c7c65fc/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24530</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>409</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr7/DOWNSAMPLED/image/jpeg/275c80cdb8491e52788ee34a27a353b6/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>119039</xocs:filesize>
               <xocs:pixel-height>623</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr3/DOWNSAMPLED/image/jpeg/a9cff7a6eab3d91b1cbf691fa63951b3/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>69966</xocs:filesize>
               <xocs:pixel-height>462</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr4/DOWNSAMPLED/image/jpeg/f71fbd83e4949a736500060e2b006ce4/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>57909</xocs:filesize>
               <xocs:pixel-height>671</xocs:pixel-height>
               <xocs:pixel-width>534</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr8/DOWNSAMPLED/image/jpeg/4758e9984d9439198772134d4827ce77/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>97606</xocs:filesize>
               <xocs:pixel-height>755</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr5/DOWNSAMPLED/image/jpeg/13b94f037c3f745ee49668ad3037cb32/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>72103</xocs:filesize>
               <xocs:pixel-height>540</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/sc1/HIGHRES/image/jpeg/4e7adb1c51a1c860f8d4a7316d869a03/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>493921</xocs:filesize>
               <xocs:pixel-height>2391</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr6/HIGHRES/image/jpeg/66ff592ae90a50506918bb06b14bc282/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>815493</xocs:filesize>
               <xocs:pixel-height>3026</xocs:pixel-height>
               <xocs:pixel-width>3161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr2/HIGHRES/image/jpeg/5da476c4b849ff416fb87fd8d6f31d9d/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>800846</xocs:filesize>
               <xocs:pixel-height>3013</xocs:pixel-height>
               <xocs:pixel-width>2369</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr1/HIGHRES/image/jpeg/7e3b91a53a9e49f421f7fc592ffd71e3/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>571426</xocs:filesize>
               <xocs:pixel-height>2895</xocs:pixel-height>
               <xocs:pixel-width>2313</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/fx1/HIGHRES/image/jpeg/72cde11b0d7d07c0c687e96c9b5fa854/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>196422</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1810</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr7/HIGHRES/image/jpeg/656cebe481ee33d62271e7d1369a6cd3/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1491992</xocs:filesize>
               <xocs:pixel-height>2759</xocs:pixel-height>
               <xocs:pixel-width>2567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr3/HIGHRES/image/jpeg/b1c6f2b189724d45fd1901e4ff2d20f3/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>675033</xocs:filesize>
               <xocs:pixel-height>2046</xocs:pixel-height>
               <xocs:pixel-width>2369</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr4/HIGHRES/image/jpeg/9b36d345e2f9011c96338ed3dda5ebf4/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>585663</xocs:filesize>
               <xocs:pixel-height>2974</xocs:pixel-height>
               <xocs:pixel-width>2367</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr8/HIGHRES/image/jpeg/f38b5b48cc0318413693633a100b1b93/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>793634</xocs:filesize>
               <xocs:pixel-height>3344</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/gr5/HIGHRES/image/jpeg/774357d44fa631b9f42f06f4515e2ce3/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>636209</xocs:filesize>
               <xocs:pixel-height>2392</xocs:pixel-height>
               <xocs:pixel-width>2368</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310372/mmc1/MAIN/application/pdf/81d6b93f1ebd49b4c8ac1788c0deca3c/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>4182334</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310372-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>2958242</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:1079G5XHS1G/MAIN/application/pdf/39fcf6125f9da7164650653c14a60ebf/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>111885</aid>
            <ce:article-number>111885</ce:article-number>
            <ce:pii>S0223-5234(19)31037-2</ce:pii>
            <ce:doi>10.1016/j.ejmech.2019.111885</ce:doi>
            <ce:copyright type="full-transfer" year="2019">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">
                     <ce:bold>(A)</ce:bold> Structures of compounds <ce:bold>I</ce:bold>, <ce:bold>II,</ce:bold> and <ce:bold>III</ce:bold>. <ce:bold>(B)</ce:bold> This table represents the inhibitory activity of three hybrids <ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, and <ce:bold>7g</ce:bold>, as well as the lead compound II towards the growth of two normal cell lines MCF10A (human breast epithelial cell line) and HFF1 (Human foreskin fibroblasts) in comparison to A375 melanoma cell line. <ce:bold>(C)</ce:bold> Percentage of NO released from compounds <ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, <ce:bold>7g</ce:bold>, <ce:bold>7h</ce:bold>, and <ce:bold>7i</ce:bold> in phosphate buffer (pH 7.4) after 2 and 48 h using a modified Griess colorimetric method (The methods section).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523419310372/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">
                     <ce:bold>(A</ce:bold>–<ce:bold>B)</ce:bold> Predicted conformations of compounds <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> in the STAT3-SH2 domain (PDB ID: <ce:inter-ref id="intref0035" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) from docking (AutoDock 4.2). <ce:bold>(A-left, B-left)</ce:bold> Represents the electrostatic potential surface for the binding pocket of the STAT3-SH2 domain with compounds <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold>. The electrostatic potential varied from −5<ce:italic>K</ce:italic>
                     <ce:inf loc="post">B</ce:inf>
                     <ce:italic>T</ce:italic>/<ce:italic>e</ce:italic> to +5<ce:italic>K</ce:italic>
                     <ce:inf loc="post">B</ce:inf>
                     <ce:italic>T</ce:italic>/<ce:italic>e</ce:italic> from red to blue. <ce:bold>(A-right, B-right)</ce:bold> Represents the trajectories for compounds <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> binding to the STAT3-SH2 domain. STAT3-SH2 residues engaging the ligand are explicitly shown in grey stick representation. The ligands are shown green ball and sticks. <ce:bold>(C)</ce:bold> The effect of <ce:bold>7</ce:bold>
                     <ce:bold>b</ce:bold>, <ce:bold>7</ce:bold>
                     <ce:bold>c</ce:bold>, and <ce:bold>7g</ce:bold> in a recombinant STAT3 displacement assay using a FAM labeled 5-GpYLPQTV-NH2 peptide; Data shows the average from two independent experiments. <ce:bold>(D)</ce:bold> The ability of <ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, <ce:bold>7g</ce:bold>, compound <ce:bold>II,</ce:bold> or different combinations of compounds <ce:bold>II</ce:bold> and <ce:bold>7g</ce:bold> to inhibit proliferation of A375 melanoma cell line. Cells were treated with different doses of each inhibitor or different doses of compound II in the presence of a fixed concentration of <ce:bold>7g</ce:bold> (12.5, 25, or 50 μM) for 48 h, and viability was determined using MTS assay (Promega). The Y-axis represents GI<ce:inf loc="post">50</ce:inf> (The concentration that resulted in 50% Growth inhibition) for each inhibitor or each combination. <ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, <ce:bold>7g</ce:bold>, and compound <ce:bold>II</ce:bold> bars represent the values shown in <ce:cross-ref id="crosref0840" refid="fig1">Fig. 1</ce:cross-ref>B. Data show the average from three independent experiments. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523419310372/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">
                     <ce:bold>(A</ce:bold>) The ability of <ce:bold>7b</ce:bold> to suppress STAT3 phosphorylation in three KRAS mutant and two wild-type cancer cell lines without affecting the upstream tyrosine kinases JAK2 and Src. <ce:bold>(B) 7b</ce:bold> and <ce:bold>7c</ce:bold> inhibited STAT3 phosphorylation in the BRAF mutant cell line A375 at both Y705 and S727 without affecting the phosphorylation of the STAT-3 activators Src and JAK2 or the phosphorylation of the STAT-3 regulated protein ERK. <ce:bold>(C) 7b</ce:bold> and <ce:bold>7c</ce:bold> inhibited STAT3 phosphorylation without affecting the phosphorylation of STAT1 at Y701, STAT5 at Y694, or STAT6 at Y641. In all these experiments, A375 cells were treated with different doses of each inhibitor for 20 h. Protein expression and phosphorylation were assessed using western blotting, actin, vinculin, or both were employed as loading controls.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523419310372/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">
                     <ce:bold>(A) 7c</ce:bold> inhibited EGF triggered nuclear translocation of STAT3 in MEF cells (Mouse Embryonic Fibroblasts), in a dose-dependent manner; Data show the average from three independent experiments; <ce:bold>(B)</ce:bold> Electrophoretic mobility shift assay (EMSA) were employed to examine the effect of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> on the DNA binding activity of STAT3 in A375 cell line using IRDye 700-labeled DNA oligo (LI-COR Biosciences), competitor oligo and oligo mutant (Santa Cruz Biotechnologies) were employed as positive and negative controls, respectively. STAT3-IP represents nuclear extract of cells where STAT3 was immune-precipitated; <ce:bold>(C) 7b</ce:bold> ability to inhibit proliferation of various BRAF/KRAS mutant and wild-type cancer cell lines. Cells were treated with different doses of <ce:bold>7</ce:bold>
                     <ce:bold>b</ce:bold> for 48 h, and viability was determined using MTS assay (Promega). The Y-axis represents <ce:bold>7</ce:bold>
                     <ce:bold>b</ce:bold> GI<ce:inf loc="post">50</ce:inf> (The concentration that resulted in 50% Growth inhibition) versus the cancer cell line on the X-axis. Data show the average from three independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523419310372/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">
                     <ce:bold>(A) 7b</ce:bold> and <ce:bold>7c</ce:bold> inhibited the anchorage-dependent growth of A375 cells in a dose-dependent manner. (Experiment has been repeated two times, and the results were consistent). <ce:bold>(B)</ce:bold> Western blot analysis showed inhibition of STAT3 phosphorylation and Cyclin D1 expression in A375 cells that were treated with different doses of <ce:bold>7b</ce:bold> then induced with IL-6. <ce:bold>(C)</ce:bold> Compound <ce:bold>7b</ce:bold> induced ROS generation in A375 cells. ROS generation was quantified using DCFH-DA staining and analysis by flow cytometry.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523419310372/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">
                     <ce:bold>(A)</ce:bold> FACS analysis of A375 cell nuclei stained with PI after treatment with DMSO, 10, and 25 μM of <ce:bold>7b</ce:bold> or <ce:bold>7c</ce:bold> for 24 h. The modeling feature of FlowJo V10 software was employed to analyze the PI fluorescence following a model that was reported by Watson et al. [<ce:cross-ref id="crosref0845" refid="bib40">40</ce:cross-ref>]. RMS (root mean square) deviation used to evaluate the goodness of the fit. The percentage of cells modeled in each experiment was comparable. <ce:bold>(B)</ce:bold> Histogram showing the percentages of cells in each phase of the cell cycle (An average of three independent experiments, error bars: SEM). <ce:bold>(C)</ce:bold> Western blot analysis showed inhibition of PAX3 and Cyclin D1 expression and induction of p-72 expression in A375 cells that were treated for one night with different doses of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> before lysis.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523419310372/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">
                     <ce:bold>(A)</ce:bold> Compounds <ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, and <ce:bold>7g</ce:bold> inhibited STAT3 phosphorylation and PAX3 expression in melanoma cell lines with SB-590885 acquired resistance. Sensitive (-S) and resistant (-R) 451 Lu and MEL 1617 melanoma cell lines were exposed to different doses of each inhibitor for 12 h before cell lysis. Protein expression of STAT3, phospho-STAT3, and PAX3 were analyzed by western blot using actin as a loading control. (Experiment was repeated at least two times (<ce:bold>B)</ce:bold> This table represents the inhibitory activity of <ce:bold>7b, 7c</ce:bold>, and <ce:bold>7g</ce:bold> towards the growth and the STAT3 transcription activity of the Sensitive and resistant 451 Lu and MEL 1617 melanoma cell lines.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523419310372/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">
                     <ce:bold>(A)</ce:bold> Compounds <ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, and <ce:bold>7g</ce:bold> inhibited STAT3 signaling in melanoma cell lines with SB-590885-acquired resistance. Sensitive (S-) and resistant (R-) 451 Lu and MEL 1617 melanoma cell lines were transfected with a mixture of inducible STAT3-responsive firefly luciferase construct and constitutively expressing renilla luciferase construct (40:1), after 48 h of transfection, cells were treated with different doses of each inhibitor with vehicle (DMSO). A dual-luciferase assay was performed. The dose-response curves represent STAT3 transcriptional activity (Experiments were done in triplicates). <ce:bold>(B–C) 7b</ce:bold> induced caspase activity and apoptosis in the 451 Lu-R cell line. <ce:bold>(B) 7b</ce:bold> induced PARP and caspase-7 cleavage in both sensitive and resistant 451 Lu cell lines. Cells were exposed to different doses of each inhibitor for 12 h before cell lysis. Protein expression of PARP, cleaved PARP and Caspase-7 were analyzed by western blot using vinculin as a loading control. (Experiment was repeated two times). <ce:bold>(C)</ce:bold> Cells were treated with different doses of compound <ce:bold>7b</ce:bold>, and then apoptosis was analyzed using the lncuCyte Caspase-3/7 reagent and lncuCyte® ZOOM equipment with a × 10 objective at indicated time points. Caspase-3/7 activity was significantly increased in a dose-dependent manner. Error bars: SEM (n = 3).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523419310372/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Synthesis of <ce:bold>6a-i</ce:bold> and the corresponding oximes <ce:bold>7a-i</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523419310372/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" orcid="0000-0003-1298-8725" author-id="S0223523419310372-04e13be3fa4414e0cb758fe99dc9d2a9">
                  <ce:given-name>Tamer S.</ce:given-name>
                  <ce:surname>Kaoud</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523419310372-45c97e54e2373f1781767d2049128703">
                  <ce:given-name>Aliaa M.</ce:given-name>
                  <ce:surname>Mohassab</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523419310372-223aa9678f47e45bb7fcd533c9b54dce">
                  <ce:given-name>Heba A.</ce:given-name>
                  <ce:surname>Hassan</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523419310372-3c6c726fe215ea2a30d4c105b7616395">
                  <ce:given-name>Chunli</ce:given-name>
                  <ce:surname>Yan</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523419310372-533f16d28a4fba309395494ae0a43b93">
                  <ce:given-name>Sabrina X.</ce:given-name>
                  <ce:surname>Van Ravenstein</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" orcid="0000-0001-7015-7124" author-id="S0223523419310372-561e301b1028102b1f902b3d0710ba1c">
                  <ce:given-name>Dalia</ce:given-name>
                  <ce:surname>Abdelhamid</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0050" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au7" author-id="S0223523419310372-547c4d88ac588fa5febf58232a4c1791">
                  <ce:given-name>Kevin N.</ce:given-name>
                  <ce:surname>Dalby</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0060" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au8" author-id="S0223523419310372-a881799089ea2530a2e2b4ef1d1b9436">
                  <ce:given-name>Mohamed</ce:given-name>
                  <ce:surname>Abdel-Aziz</ce:surname>
                  <ce:cross-ref id="crosref0065" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523419310372-b43eca992b5bb37e35b7221219965ee1">
                  <ce:label>a</ce:label>
                  <ce:textfn>Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Division of Chemical Biology and Medicinal Chemistry</sa:organization>
                     <sa:organization>College of Pharmacy</sa:organization>
                     <sa:organization>The University of Texas at Austin</sa:organization>
                     <sa:city>Austin</sa:city>
                     <sa:state>TX</sa:state>
                     <sa:postal-code>78712</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, the University of Texas at Austin, Austin, TX, 78712, USA</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523419310372-f1902b76b28610755264f11120adaf78">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>Faculty of Pharmacy</sa:organization>
                     <sa:organization>Minia University</sa:organization>
                     <sa:city>Minia</sa:city>
                     <sa:postal-code>61519</sa:postal-code>
                     <sa:country>Egypt</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523419310372-ed35727c35fc747800dd0f09b6c195b9">
                  <ce:label>c</ce:label>
                  <ce:textfn>Department of Chemistry, Georgia State University, Atlanta, GA, 30302, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Chemistry</sa:organization>
                     <sa:organization>Georgia State University</sa:organization>
                     <sa:city>Atlanta</sa:city>
                     <sa:state>GA</sa:state>
                     <sa:postal-code>30302</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Department of Chemistry, Georgia State University, Atlanta, GA, 30302, USA</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="14" month="9" year="2019"/></ce:date-received>
            <ce:date-revised day="12" month="11" year="2019"/></ce:date-revised>
            <ce:date-accepted day="12" month="11" year="2019"/></ce:date-accepted>
            <ce:abstract class="author" id="abs0010" xml:lang="en" view="all"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Constitutive activation of STAT3 can play a vital role in the development of melanoma. STAT3-targeted therapeutics are reported to show efficacy in melanomas harboring the BRAFV600E mutant and also in vemurafenib-resistant melanomas. We designed and synthesized a series of substituted nitric oxide (NO)-releasing quinolone-1,2,4-triazole/oxime hybrids, hypothesizing that the introduction of a STAT3 binding scaffold would augment their cytotoxicity. All the hybrids tested showed a comparable level of <ce:italic>in vitro</ce:italic> NO production. <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> exhibited direct binding to the STAT3-SH domain with IC<ce:inf loc="post">50</ce:inf> of ∼ 0.5 μM. Also, they abrogated STAT3 tyrosine phosphorylation in several cancer cell lines, including the A375 melanoma cell line that carries the BRAFV600E mutation. At the same time, they did not affect the phosphorylation of upstream kinases or other STAT isoforms. <ce:bold>7c</ce:bold> inhibited STAT3 nuclear translocation in mouse embryonic fibroblast while <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> inhibited STAT3 DNA-binding activity in the A375 cell line. Their anti-proliferating activity is attributed to their ability to trigger the production of reactive oxygen species and induce G1 cell cycle arrest in the A375 cell line. Interestingly, <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> showed robust cell growth suppression and apoptosis induction in two pairs of BRAF inhibitor-naïve (-S) and resistant (-R) melanoma cell lines containing a BRAF V600E mutation. Surprisingly, MEL1617-R cells that are known to be more resistance to MEK inhibition by GSK1120212 than MEL1617-S cells exhibit a similar response to <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold>.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523419310372/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords class="keyword" id="kwrds0010" xml:lang="en" view="all">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Quinolines</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Triazoles</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>STAT3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>NO donors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Melanoma</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0035">
                  <ce:text>Acquired resistance to BRAF-Inhibition</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0040">
                  <ce:text>BRAF V600E mutant</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0035" view="all">Malignant melanoma is an aggressive form of skin cancer that arises from the unregulated proliferation of melanocytes [<ce:cross-ref id="crosref0070" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0075" refid="bib2">2</ce:cross-ref>]. Despite its low incidence (only 4% of all dermatologic cancers), it is responsible for 80% of deaths from skin cancer and is characterized by a low survival rate. Vemurafenib is an FDA approved BRAF inhibitor used for metastatic melanoma patients, but the development of resistance to this drug represents a significant hurdle to successful treatment [<ce:cross-ref id="crosref0080" refid="bib3">3</ce:cross-ref>]. This resistance occurs through several mechanisms, which often involve the reactivation of ERK, but also includes mechanisms independent of ERK reactivation [<ce:cross-ref id="crosref0085" refid="bib1">1</ce:cross-ref>].</ce:para>
                  <ce:para id="p0040" view="all">Signal transducers and activators of transcription (STATs 1–4, 5a-b and 6) are a family of transcription proteins that regulate gene expression related to cellular processes, including proliferation, differentiation, angiogenesis, apoptosis, and immune response [<ce:cross-ref id="crosref0090" refid="bib4">4</ce:cross-ref>]. STAT3 is activated through cytokine (e.g. interleukins) or growth factor (e.g. EGF) binding to cell surface receptors, which results in its phosphorylation at Tyr705, followed by dimerization and translocation to the nucleus, where it binds to specific DNA sequences, and induces transcription [<ce:cross-ref id="crosref0095" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0100" refid="bib5">5</ce:cross-ref>]. STAT3 possesses a secondary phosphorylation site, Ser727, whose phosphorylation is essential for maximal transcriptional activity [<ce:cross-ref id="crosref0105" refid="bib6">6</ce:cross-ref>]. In normal cells, the duration of STAT3 activation is transient, however; in cancer cells, STAT3 signaling is often constitutive [<ce:cross-ref id="crosref0110" refid="bib4">4</ce:cross-ref>].</ce:para>
                  <ce:para id="p0045" view="all">STAT3 may play a role in melanoma development. For example, the expression of a STAT3 dominant-negative variant was found to cause inhibition of tumor growth and induce cell death in murine B16 melanoma cells [<ce:cross-ref id="crosref0115" refid="bib7">7</ce:cross-ref>]. However, while STAT3 induces growth inhibition of normal melanocytes and early-stage melanoma cells, it promotes growth of advanced melanomas [<ce:cross-ref id="crosref0120" refid="bib8">8</ce:cross-ref>] and notably, blockage of activated STAT3 in metastatic cells suppresses their invasiveness, and inhibits tumor growth and metastasis in nude mice [<ce:cross-ref id="crosref0125" refid="bib9">9</ce:cross-ref>]. Mutant BRAF is known as a significant driver of proliferation, metastasis, and survival of almost 50% of melanomas. Interestingly, Becker et al. [<ce:cross-ref id="crosref0130" refid="bib10">10</ce:cross-ref>] report that phosphorylation of STAT3 in melanoma is enhanced by the existence of the BRAF (V600E) mutant. STAT3 activation leads to phosphorylation and stabilization of the anti-apoptotic protein Mcl-1 that drives melanoma survival and chemoresistance.</ce:para>
                  <ce:para id="p0050" view="all">Several small-molecule inhibitors of BRAF were developed a few years ago, including vemurafenib and dabrafenib. However, these inhibitors generally exhibit a temporary response, in patients with BRAF-mutant melanomas [<ce:cross-refs id="crosrefs0010" refid="bib11 bib12 bib13 bib14">11–14</ce:cross-refs>]. Notarangelo et al. [<ce:cross-ref id="crosref0135" refid="bib15">15</ce:cross-ref>] reported that the IL6/STAT3 axis is one of the primary regulators of acquired resistance to a BRAF inhibitor in BRAF mutant thyroid carcinoma cells. Exposure of cells to PLX4032 (BRAF inhibitor) triggered reprogramming of the expression of several genes, including JAK/STAT3. Interestingly, the dual targeting of BRAF and STAT3 in these cells showed an enhanced response with minimal acquired resistance to the BRAF inhibition [<ce:cross-ref id="crosref0140" refid="bib15">15</ce:cross-ref>]. Moreover, another recent report suggested that targeting the STAT3–paired box homeotic gene 3 (PAX3)-signaling pathway could overcome acquired resistance to vemurafenib and it was suggested that combination-targeted therapies could provide a plausible solution to overcome this resistance in melanoma patients [<ce:cross-ref id="crosref0145" refid="bib3">3</ce:cross-ref>].</ce:para>
                  <ce:para id="p0055" view="all">Over the past years, many peptidic and non-peptidic STAT3 inhibitors have been discovered to inhibit STAT3 phosphorylation and dimerization. However, to date, none of these have been marketed due to either lack of efficacy (e.g., e STA-21, LLL-3, curcumin, and their analogs) or unusual side effect profiles (e.g., OPB51602 and OPB-31121) [<ce:cross-refs id="crosrefs0015" refid="bib16 bib17 bib18 bib19">16–19</ce:cross-refs>]. A new generation of OPB compounds are currently being evaluated in early phase clinical trials, and so far show improved toxicity profiles [<ce:cross-ref id="crosref0150" refid="bib19">19</ce:cross-ref>].</ce:para>
                  <ce:para id="p0060" view="all">Here we report the design and synthesis of novel anticancer hybrids comprised of a quinoline, a triazole, and an oxime moiety (nitric oxide donor). Quinoline-containing scaffolds are well-recognized as chemotherapeutic anticancer agents [<ce:cross-ref id="crosref0155" refid="bib20">20</ce:cross-ref>]. Many triazoles and bistriazoles possess pharmacological activities (e.g., antibacterial, antifungal, anti-inflammatory, and anticancer) [<ce:cross-ref id="crosref0160" refid="bib21">21</ce:cross-ref>] and several triazoles have been incorporated into clinically approved drugs [<ce:cross-ref id="crosref0165" refid="bib22">22</ce:cross-ref>]. These heterocycles possess significant dipole moments that are capable of forming favorable hydrogen bonds to biomolecules [<ce:cross-ref id="crosref0170" refid="bib23">23</ce:cross-ref>]. Recently, several triazoles have been reported to suppress STAT3 phosphorylation [<ce:cross-ref id="crosref0175" refid="bib22">22</ce:cross-ref>,<ce:cross-ref id="crosref0180" refid="bib24">24</ce:cross-ref>]. In addition, numerous reports (reviewed recently, [<ce:cross-ref id="crosref0185" refid="bib25">25</ce:cross-ref>]) have shown that exposure to elevated concentrations of NO can suppress cancer progression.</ce:para>
                  <ce:para id="p0065" view="all">Compounds <ce:bold>I</ce:bold> and <ce:bold>II</ce:bold> (<ce:cross-ref id="crosref0190" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>A) were previously reported to inhibit STAT3 SH2 domains [<ce:cross-ref id="crosref0195" refid="bib26">26</ce:cross-ref>,<ce:cross-ref id="crosref0200" refid="bib27">27</ce:cross-ref>]. Compound <ce:bold>I</ce:bold> suppresses cell progression and induces apoptosis in breast and pancreatic cancer cell lines. It inhibits the proliferation of MDA-MB-231 and MCF7 cell lines with IC<ce:inf loc="post">50s</ce:inf> of 0.1 and 0.29 μM, respectively. Treatment of MDA-MB-231 cells with 5 μM of compound <ce:bold>I</ce:bold> inhibits STAT3 transcription by 65%, compared to a non-treated control [<ce:cross-ref id="crosref0205" refid="bib26">26</ce:cross-ref>]. Compound <ce:bold>II</ce:bold> inhibits STAT3 transcriptional activity in HeLa cells with an IC<ce:inf loc="post">50</ce:inf> of 74 μM [<ce:cross-ref id="crosref0210" refid="bib27">27</ce:cross-ref>]. We docked these compounds onto the STAT3 SH2 domain (PDB code: <ce:inter-ref id="intref0010" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) using AutoDock Vina [<ce:cross-ref id="crosref0215" refid="bib26">26</ce:cross-ref>,<ce:cross-ref id="crosref0220" refid="bib28">28</ce:cross-ref>,<ce:cross-ref id="crosref0225" refid="bib29">29</ce:cross-ref>] and found that the 2-phenyl group on the quinoline ring fits effectively into a hydrophobic cleft near to Ile634. In this current study, a newly designed scaffold <ce:bold>(III)</ce:bold> (<ce:cross-ref id="crosref0230" refid="fig1">Fig. 1</ce:cross-ref>A), comprised of a quinoline and triazole motif, was selected based on its similarity to compounds <ce:bold>I</ce:bold> and <ce:bold>II</ce:bold> and was combined with an oxime-based NO donor to augment its STAT3 inhibitory properties with the cytotoxic release of nitric oxide.</ce:para>
                  <ce:para id="p0070" view="all">Here we set out to develop a novel series of hybrids based on scaffold <ce:bold>III</ce:bold> (<ce:cross-ref id="crosref0235" refid="fig1">Fig. 1</ce:cross-ref>A) to identify promising anticancer candidates with the potential to overcome BRAF-inhibitor acquired resistance in melanoma cells. The structural variability of the hybrid compounds was obtained by using different substituents (<ce:bold>R</ce:bold>, <ce:bold>R</ce:bold>
                     <ce:bold>’</ce:bold> 
                     <ce:bold>and R’’</ce:bold>) as shown in <ce:cross-ref id="optmQ34aF4uB3" refid="sch1">Scheme 1</ce:cross-ref>
                     <ce:float-anchor refid="sch1"/></ce:float-anchor>. Compounds were chemically synthesized, and then their ability to release NO, bind STAT3, suppress STAT3 activity and inhibit cancer cell growth were evaluated in several cancer cell lines, including both SB-590885-sensitive and SB-590885 -resistant melanoma cell lines.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0075" view="all">The reaction sequence employed to synthesize the target compounds is outlined in <ce:cross-ref id="crosref0240" refid="sch1">Scheme 1</ce:cross-ref>. The initial 2-(substituted phenyl) quinoline-4-carboxylic acids <ce:bold>1a–f</ce:bold> were obtained by reacting 5-methoxyisatin or isatin with an appropriate acetophenone. These acids were then refluxed with absolute ethanol in the presence of conc. H<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf> to afford the corresponding esters <ce:bold>2a-f.</ce:bold> Afterward, the ethyl esters <ce:bold>2a-f</ce:bold> were converted to carbohydrazide derivatives <ce:bold>3a-f</ce:bold> 
                        <ce:italic>via</ce:italic> reaction with hydrazine monohydrate. The formation of these intermediates was confirmed by their reported melting points. The carbohydrazides were heated at reflux with allyl or phenyl isothiocyanate in ethanol. This was followed by the addition of 2 N NaOH, then acidification with conc. HCl, affording 1,2,4-triazole-3-thiol derivatives <ce:bold>4a-i</ce:bold>. The chemical identity of the synthesized compounds was confirmed by <ce:sup loc="post">1</ce:sup>H NMR and <ce:sup loc="post">13</ce:sup>C NMR spectra. Compound <ce:bold>5</ce:bold> was prepared through acetylation of p-aminoacetophenone with bromoacetyl bromide in the presence of potassium carbonate. Afterward, compound 5 was then coupled with the 1,2,4-triazole derivatives <ce:bold>4a-i</ce:bold> in acetonitrile in the presence of triethylamine affording the nine ketone intermediates <ce:bold>6a-i</ce:bold>. The final nine NO-donating oxime derivatives <ce:bold>7a-i</ce:bold> were prepared by reacting compounds <ce:bold>6a-i</ce:bold> with hydroxylamine hydrochloride in the presence of anhydrous sodium acetate.<ce:display>
                           <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="undtbl1" rowsep="0">
                              <tgroup cols="16">
                                 <colspec colname="col1" colnum="1"/></colspec>
                                 <colspec colname="col2" colnum="2"/></colspec>
                                 <colspec colname="col3" colnum="3"/></colspec>
                                 <colspec colname="col4" colnum="4"/></colspec>
                                 <colspec colname="col5" colnum="5"/></colspec>
                                 <colspec colname="col6" colnum="6"/></colspec>
                                 <colspec colname="col7" colnum="7"/></colspec>
                                 <colspec colname="col8" colnum="8"/></colspec>
                                 <colspec colname="col9" colnum="9"/></colspec>
                                 <colspec colname="col10" colnum="10"/></colspec>
                                 <colspec colname="col11" colnum="11"/></colspec>
                                 <colspec colname="col12" colnum="12"/></colspec>
                                 <colspec colname="col13" colnum="13"/></colspec>
                                 <colspec colname="col14" colnum="14"/></colspec>
                                 <colspec colname="col15" colnum="15"/></colspec>
                                 <colspec colname="col16" colnum="16"/></colspec>
                                 <thead>
                                    <row rowsep="1" valign="top">
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">1a</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">1b</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">1c</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">1d</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">1e</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">1f</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4a</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4b</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4c</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4d</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4e</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4f</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4g</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4h</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd">4i</entry>
                                    </row>
                                 </thead>
                                 <tbody>
                                    <row valign="top">
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-Cl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4- OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-Cl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3,4-di OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-Cl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-Cl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-Cl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3/4-OMe</entry>
                                    </row>
                                    <row valign="top">
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R’</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                    </row>
                                    <row valign="top">
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R’’</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allyl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allyl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allyl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                    </row>
                                    <row valign="top">
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7a</bold>
                                       </entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7b</bold>
                                       </entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7c</bold>
                                       </entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7d</bold>
                                       </entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7e</bold>
                                       </entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7f</bold>
                                       </entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7g</bold>
                                       </entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7h</bold>
                                       </entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                                          <bold>7i</bold>
                                       </entry>
                                    </row>
                                    <row valign="top">
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-Cl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-Cl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-Cl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3/4-OMe</entry>
                                    </row>
                                    <row valign="top">
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R’</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                                    </row>
                                    <row valign="top">
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R’’</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allyl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allyl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allyl</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                       <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                                    </row>
                                 </tbody>
                              </tgroup>
                           </ce:table>
                        </ce:display>
                     </ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Biology</ce:section-title>
                     <ce:section id="sec2.2.1" view="all">
                        <ce:label>2.2.1</ce:label>
                        <ce:section-title id="sectitle0050">Screening of anticancer activity and SAR analysis</ce:section-title>
                        <ce:para id="p0080" view="all">The overexpression or constitutive activation of STAT3 has been identified in almost 70% of solid and hematological human tumors, and its constitutive activation correlates with poor survival [<ce:cross-ref id="crosref0245" refid="bib4">4</ce:cross-ref>]. Accordingly, the anticancer activity of the hybrids developed in this study was evaluated in several cancer cell lines. A total of eighteen compounds were synthesized: 9 ketones and 9 oximes. Eleven compounds, <ce:bold>6a, 6e, 6g,</ce:bold> and <ce:bold>7b-i,</ce:bold> were selected by the National Cancer Institute (NCI) for anticancer screening according to the protocol of the Drug Evaluation Branch of the National Cancer Institute, Bethesda, USA. <ce:italic>In vitro</ce:italic> anticancer screening was carried out in 60 cell lines of nine different cancer cell types; ovarian, renal, prostate, leukemia, melanoma, lung, colon, CNS, and breast cancers. Compounds were added at a single concentration of 10 μM for 48 h. Endpoint determinations were made using a protein-binding dye, sulforhodamine B (SRB), that enables quantification of the number of cells in each well. Results for each compound were reported as the growth percent inhibition of the treated cells, which are evaluated spectrophotometrically and compared to that of the untreated control cells.</ce:para>
                        <ce:para id="p0085" view="all">Oximes <ce:bold>7b-i</ce:bold> showed promising anticancer activity varying from moderate to significant growth inhibition against most of the 60 cancer cell lines. <ce:bold>7b, 7c, and 7f</ce:bold> were the most effective hybrids against the cell lines shown in <ce:cross-ref id="crosref0250" refid="appsec1">Table S1</ce:cross-ref>. Compound <ce:bold>7b</ce:bold> showed inhibitory activity against leukemia (MOLT-4 and CCRF-CEM), melanoma (LOX IMVI and UACC-62), ovarian (IGROV1), and breast (MCF7 and T-47D) cancer cell lines with percent growth inhibition in the range of 76–100%. Compound <ce:bold>7c</ce:bold> was effective against leukemia, non-small cell lung, and colon cancer cell lines. Furthermore, it incurred significant growth inhibition, with complete cell death in leukemia (MOLT-4), melanoma (LOX IMVI), ovarian (IGROVI) and renal (UO-31) cell lines (<ce:cross-ref id="crosref0255" refid="appsec1">Table S1</ce:cross-ref>). Compound <ce:bold>7f</ce:bold> caused complete cell death against both leukemia (HL-60 (TB)) and breast (T-47D) cancer cell lines and induced potent growth inhibition (81–98%) against the leukemia cell lines; (CCRF-CEM, K-562, MOLT-4, and RPMI-8226). Compound <ce:bold>7f</ce:bold> also inhibited the growth of the A549/ATCC and NCI-H522 non-small cell lung cancer cell lines as well as the colon cancer cell line, COLO 205, and several other cell lines (<ce:cross-ref id="crosref0260" refid="appsec1">Table S1</ce:cross-ref>).</ce:para>
                        <ce:para id="p0090" view="all">We also assessed three of the hybrids (<ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold> and <ce:bold>7g</ce:bold>) and the lead compound II (STX-0119, structure shown in <ce:cross-ref id="crosref0265" refid="fig1">Fig. 1</ce:cross-ref>A and purchased from Key Organics Limited) for their ability to inhibit the growth of the non-cancer cell lines, MCF10A (human breast epithelial cell line) and HFF1 (Human foreskin fibroblasts). The data shown in <ce:cross-ref id="crosref0270" refid="fig1">Fig. 1</ce:cross-ref>B reveal a relative resistance of these cells to the hybrids when compared to the melanoma cell line A375 (<ce:cross-ref id="crosref0275" refid="fig1">Fig. 1</ce:cross-ref>B). For example, <ce:bold>7c</ce:bold> inhibited cellular growth of HFF1 and MCF10A with IC<ce:inf loc="post">50</ce:inf> values of 200 ± 11 and 93 ± 7.3 μM compared to an IC<ce:inf loc="post">50</ce:inf> of 1.9 ± 1.5 μM for the A375 cells.</ce:para>
                        <ce:para id="p0095" view="all">For most cell lines, compound <ce:bold>7c</ce:bold> was the most potent of the compounds tested. For example, against the A375 melanoma cell line, it exhibited a growth inhibition IC<ce:inf loc="post">50</ce:inf> of 1.9 ± 1.5 μM, <ce:cross-ref id="crosref0280" refid="fig1">Fig. 1</ce:cross-ref>B. <ce:bold>7c</ce:bold> is characterized by the presence of an electron-withdrawing <ce:italic>p</ce:italic>-chlorophenyl group as well as <ce:italic>N</ce:italic>-4 allyl moiety. Absence of the chloro substituent in compound <ce:bold>7b</ce:bold> decreased its ability to inhibit the growth of several NCI cell lines, including the A375 cell line that showed a growth inhibition IC<ce:inf loc="post">50</ce:inf> of 7.7 ± 1.3 μM (<ce:cross-ref id="crosref0285" refid="fig1">Fig. 1</ce:cross-ref>B). Replacement of the <ce:italic>N</ce:italic>-4 allyl group of compound <ce:bold>7c</ce:bold> with a bulky phenyl ring completely diminished the activity in compound <ce:bold>7d</ce:bold>. Also, replacement of the chloro group with an electron-donating methoxy group (e.g., <ce:bold>7f</ce:bold>), moderately enhanced the activity compared to <ce:bold>7c</ce:bold> (<ce:cross-ref id="crosref0290" refid="appsec1">Table S1</ce:cross-ref>). The activity of <ce:bold>7f</ce:bold> sharply declined upon replacement of the <ce:italic>N</ce:italic>-4 allyl moiety with a phenyl ring (<ce:bold>7e</ce:bold>). Compounds <ce:bold>7h</ce:bold> and <ce:bold>7i,</ce:bold> showed an average growth inhibition percent, with the presence of electron-donating methoxy and dimethoxy substituents decreasing the overall anticancer activity against most of the cell lines, except for the melanoma LOX IMVI cell line. In conclusion, compounds with a ketonic group showed very weakly, or no activity against most of the cancer cell lines tested (compounds <ce:bold>6a, 6e</ce:bold>, and <ce:bold>6g</ce:bold>). While the oximes (compounds <ce:bold>7b-i</ce:bold>), exhibited an increase in the activity against most of the cancer cell lines tested, consistent with a role for NO in the activity. Also, compounds with a small substituent (allyl group) on the triazole ring exhibited better activity than those with large substituent (phenyl group) (compound <ce:bold>7c</ce:bold> versus <ce:bold>7d</ce:bold>).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.2" view="all">
                        <ce:label>2.2.2</ce:label>
                        <ce:section-title id="sectitle0055">NO-releasing hybrids</ce:section-title>
                        <ce:para id="p0100" view="all">In 2008, Thomas et al. [<ce:cross-ref id="crosref0295" refid="bib30">30</ce:cross-ref>] investigated the effect of nitric oxide (NO) on MCF7 cells. While lower levels of NO promoted cell survival and proliferation, higher levels of NO (<ce:italic>c.a.</ce:italic> 400 nM) induced apoptosis, cell cycle arrest, and cytotoxicity. In order to determine if our hybrids can produce the high level of nitric oxide, sufficient to induce cytotoxicity, the ability of each hybrid to donate NO was estimated using the modified Griess colorimetric method (<ce:cross-ref id="crosref0300" refid="fig1">Fig. 1</ce:cross-ref>C). Five hybrids (<ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, <ce:bold>7g, 7h,</ce:bold> and <ce:bold>7i)</ce:bold> were tested after 2 and 48 h of incubation at room temperature in phosphate buffer (pH 7.4) and each showed a comparable ability to release NO in phosphate buffer corresponding to 15–28% (mole NO/mole hybrid) after 2 h and increased to 30–85% (mole NO/mole compound) after 48 h (<ce:cross-ref id="crosref0305" refid="fig1">Fig. 1</ce:cross-ref>C).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.3" view="all">
                        <ce:label>2.2.3</ce:label>
                        <ce:section-title id="sectitle0060">Direct binding to the STAT3 SH2 domain</ce:section-title>
                        <ce:para id="p0105" view="all">A binding mode for the binding of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> to the STAT3-SH2 domain was predicted using molecular docking (<ce:cross-ref id="crosref0310" refid="fig2">Fig. 2</ce:cross-ref>
                           <ce:float-anchor refid="fig2"/></ce:float-anchor>A and B respectively). Docking calculations were carried using AutoDock4.21 (method section) based on the X-ray structure of the STAT3β homodimer (PDB ID: 1BG15)<ce:sup loc="post">28</ce:sup>. The docking scores for compounds <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> were −10.37 and −9.89 kcal mol<ce:sup loc="post">−1</ce:sup>, respectively. Therefore, compound <ce:bold>7b</ce:bold> can form a slightly more energetically favorable interaction with STAT3-SH2 than <ce:bold>7c</ce:bold>. As shown in <ce:cross-ref id="crosref0315" refid="fig2">Fig. 2</ce:cross-ref>A and B, the 2-phenyl rings of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> are inserted into the hydrophobic cleft formed by I634, V637. P639 and T632. The OH group in the NO of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> is also stabilized via hydrogen bonds to the side chains of R595.</ce:para>
                        <ce:para id="p0110" view="all">To further investigate the direct binding of the new compounds with the SH2 domain of STAT3, we developed a displacement assay to estimate the ability of these compounds to displace the 5-FAM-GpYLPQTV-NH2 peptide [<ce:cross-ref id="crosref0320" refid="bib31">31</ce:cross-ref>] from recombinant GST-STAT3 (<ce:cross-ref id="crosref0325" refid="fig2">Fig. 2</ce:cross-ref>C). <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> showed robust ability to displace the phospho-peptide in a dose-dependent manner (IC<ce:inf loc="post">50</ce:inf>s 0.32 ± 0.19 and 0.25 ± 0.13 μM, respectively) while <ce:bold>7g</ce:bold> did not show any tendency to bind the STAT3 SH2 domain as it was not able to entirely displace the peptide from the surface of GST-STAT3 (<ce:cross-ref id="crosref0330" refid="fig2">Fig. 2</ce:cross-ref>C).</ce:para>
                        <ce:para id="p0115" view="all">It is noticeable in the NCI screening results shown in <ce:cross-ref id="crosref0335" refid="appsec1">Table S1</ce:cross-ref> that despite the limited growth inhibition caused by the two oximes <ce:bold>7e</ce:bold> and <ce:bold>7g</ce:bold>, their corresponding ketones <ce:bold>6e</ce:bold> and <ce:bold>6g</ce:bold> showed no growth inhibition in comparison (compare <ce:bold>7g</ce:bold> and <ce:bold>6g</ce:bold> in <ce:cross-ref id="crosref0340" refid="appsec1">Table S1</ce:cross-ref>), supporting the notion that the nitric oxide (NO) donating ability of <ce:bold>7e</ce:bold> and <ce:bold>7g</ce:bold> contributes to the inhibition of cancer cell proliferation [<ce:cross-ref id="crosref0345" refid="bib25">25</ce:cross-ref>]. These results directly correlate with the ability of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> to inhibit cancer cell proliferation by both targeting the STAT3 SH2 domain and releasing NO while the mild cytotoxicity observed for <ce:bold>7g</ce:bold> was likely due to its ability to produce NO (<ce:cross-ref id="crosref0350" refid="appsec1">Table S1</ce:cross-ref> and <ce:cross-ref id="crosref0355" refid="fig1">Fig. 1</ce:cross-ref>C).</ce:para>
                        <ce:para id="p0120" view="all">In order to assess the value of combining dual functions into single hybrid molecules, an experiment was conducted where the cytotoxicity of compounds <ce:bold>II</ce:bold> (Lead STAT3 inhibitor, <ce:cross-ref id="crosref0360" refid="fig1">Fig. 1</ce:cross-ref>A), compounds <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> (STAT3 inhibitor with NO-releasing moiety) and compound <ce:bold>7g</ce:bold> (NO-releasing compound) were compared, in addition to different combinations of compounds <ce:bold>II</ce:bold> and <ce:bold>7g</ce:bold> against A375 melanoma cell line. The results shown in <ce:cross-ref id="crosref0365" refid="fig2">Fig. 2</ce:cross-ref>D revealed higher potency of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> hybrids towards the A375 cell line if compared to compound <ce:bold>II</ce:bold> (IC<ce:inf loc="post">50s</ce:inf> of 7.7, 1.9, and 16.2 μM, respectively) or compound <ce:bold>7g</ce:bold> alone. Addition of the NO-releasing <ce:bold>7g</ce:bold> to compound <ce:bold>II</ce:bold> exhibited an additive cytotoxic effect where compound <ce:bold>II</ce:bold> IC<ce:inf loc="post">50</ce:inf> towards A375 cells decreased from 16.2 ± 1.6 to 6.8 ± 1.3 μM in the presence of 12.5 μM <ce:bold>7g</ce:bold>, which is similar to the IC<ce:inf loc="post">50</ce:inf> of <ce:bold>7b</ce:bold> against the same cell line (<ce:cross-ref id="crosref0370" refid="fig2">Fig. 2</ce:cross-ref>D). The additive effects observed between <ce:bold>7g</ce:bold> and compound <ce:bold>II</ce:bold> validates the design of these hybrids where the cytotoxicity of the released NO enhances the cytotoxicity caused by STAT3 pathway inhibition.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.4" view="all">
                        <ce:label>2.2.4</ce:label>
                        <ce:section-title id="sectitle0065">The designed hybrids are selective STAT3 inhibitors <ce:italic>in cancer cells</ce:italic>
                        </ce:section-title>
                        <ce:para id="p0125" view="all">In order to rationalize the anticancer activity of these hybrids and to understand if it correlates with their ability to inhibit STAT3 and/or to donate NO, it was essential to study their molecular mechanism of action in more detail. Compounds 7<ce:bold>b</ce:bold> and <ce:bold>7c</ce:bold> exhibited toxic effect on most of the cancer cell lines tested (<ce:cross-ref id="crosref0375" refid="appsec1">Table S1</ce:cross-ref>). This significant cytotoxic activity may be attributed to their ability to bind and inhibit STAT3 activity [<ce:cross-ref id="crosref0380" refid="bib32">32</ce:cross-ref>], besides their ability to release nitric oxide.</ce:para>
                        <ce:para id="p0130" view="all">
                           <ce:bold>7b and 7c inhibited STAT3 tyrosine phosphorylation in different cancer cell lines without affecting the upstream kinases</ce:bold> - To examine the ability of the new compounds to inhibit STAT3 signaling, different cancer cell lines, including the glioblastoma U87-MG, the breast cancer cell line MDA-MB-468, the pancreatic carcinoma cell line Miapaca-2 and the non-small cell lung cancer cell lines NCI–H157 and A549 were incubated with 25 μM of <ce:bold>7b</ce:bold> overnight, before lysing the cells and immunoblotting. The melanoma cell line A375 that expresses the BRAF V600E mutant was exposed to different doses of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> (0, 5, 10, 25 and 50 μM) following the same protocol. As shown in <ce:cross-ref id="crosref0385" refid="fig3">Fig. 3</ce:cross-ref>
                           <ce:float-anchor refid="fig3"/></ce:float-anchor>A and B, <ce:bold>7b</ce:bold> exhibited a robust inhibition of STAT3 phosphorylation at Y705 and S727 in all the cell lines tested with enhanced potency in A375 cells. <ce:bold>7c</ce:bold> inhibited the phosphorylation of STAT3 in A375 cell line with lower potency than <ce:bold>7b (</ce:bold>5–10 μM of <ce:bold>7b</ce:bold> or 10–25 μM <ce:bold>7c</ce:bold> were enough to inhibit STAT3 phosphorylation) (<ce:cross-ref id="crosref0390" refid="fig3">Fig. 3</ce:cross-ref>B). Interestingly, <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> did not show any effect on the phosphorylation of the upstream tyrosine kinases (JAK2 and Src) in all the cell lines tested or ERK1/2 in A375 cell line (<ce:cross-ref id="crosref0395" refid="fig3">Fig. 3</ce:cross-ref>A and B).</ce:para>
                        <ce:para id="p0135" view="all">
                           <ce:bold>The selectivity of 7b and 7c towards</ce:bold> 
                           <ce:bold>other</ce:bold> 
                           <ce:bold>STAT</ce:bold> 
                           <ce:bold>isoform</ce:bold>
                           <ce:bold>s</ce:bold> 
                           <ce:bold>-</ce:bold> We showed earlier that <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> directly bind the STAT3 SH2 domain and inhibit STAT3 phosphorylation in A375 cell line without affecting upstream kinases (<ce:cross-refs id="crosrefs0020" refid="fig2 fig3">Figs. 2C and 3</ce:cross-refs>B). In this experiment, we investigated the selectivity towards other STAT isoforms, including STAT1, STAT5, and STAT6 (<ce:cross-ref id="crosref0400" refid="fig3">Fig. 3</ce:cross-ref>C). Immunoblots shown in <ce:cross-ref id="crosref0405" refid="fig3">Fig. 3</ce:cross-ref>C for A375 cells incubated with different doses of <ce:bold>7b</ce:bold> or <ce:bold>7c</ce:bold> overnight suggest that neither inhibitor inhibits the phosphorylation of STAT1 at Y701, STAT5 at Y694 nor STAT6 at Y641 even at high inhibitor concentrations (50 μM). This suggests that <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> are selective STAT3 inhibitors in the BRAF V600E mutant A375 melanoma cell line.</ce:para>
                        <ce:para id="p0140" view="all">
                           <ce:bold>7c inhibited STAT3 nuclear translocation -</ce:bold> STAT3 immunostaining in mouse embryonic fibroblasts (MEF) that were maintained overnight in serum-free media, revealed the existence of most of the non-phosphorylated STAT3 in the cytoplasm. Induction of STAT3 phosphorylation by EGF for 30 min before staining triggered the migration of around 60–70% of the STAT3 molecules to the nucleus (<ce:cross-ref id="crosref0410" refid="fig4">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>A). These observations are comparable to previous reports [<ce:cross-ref id="crosref0415" refid="bib33">33</ce:cross-ref>,<ce:cross-ref id="crosref0420" refid="bib34">34</ce:cross-ref>]. Cells that were incubated in serum-free media containing different doses of <ce:bold>7c</ce:bold> for the same time abrogated the EGF response and prevented the migration of STAT3 to the nucleus in a dose-dependent manner (<ce:cross-ref id="crosref0425" refid="fig4">Fig. 4</ce:cross-ref>A). This suggests that <ce:bold>7c</ce:bold> can target STAT3 in MEFs to inhibit its phosphorylation and nuclear translocation.</ce:para>
                        <ce:para id="p0145" view="all">
                           <ce:bold>7b and 7c inhibit the DNA-binding activity of STAT3 -</ce:bold> To examine the ability of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> to inhibit the DNA-binding activity of STAT3 in the A375 melanoma cell line, EMSA (Electrophoretic Mobility Shift Assay) was performed using an IRDye® 700 STAT3 consensus oligonucleotide and nuclear extract of A375 cells following the manufacture protocol (methods section) [<ce:cross-refs id="crosrefs0025" refid="bib35 bib36 bib37">35–37</ce:cross-refs>]. As shown in <ce:cross-ref id="crosref0430" refid="fig4">Fig. 4</ce:cross-ref>B, STAT3 binding to the IRDY 700 oligo was confirmed using a competitor oligo and its mutant. As a further control, STAT3 was immunoprecipitated from cells. Cells treated overnight with different doses of <ce:bold>7b</ce:bold> or <ce:bold>7c</ce:bold> before nuclear extraction showed significant dose-dependent inhibition of the DNA binding activity of STAT3 (<ce:cross-ref id="crosref0435" refid="fig4">Fig. 4</ce:cross-ref>B).</ce:para>
                        <ce:para id="p0150" view="all">The data presented in this section suggest that the hybrids specifically target the STAT3 isoform in cancer cells (<ce:cross-ref id="crosref0440" refid="fig2">Fig. 2</ce:cross-ref>A, B and 2C), to suppress its phosphorylation (<ce:cross-ref id="crosref0445" refid="fig3">Fig. 3</ce:cross-ref>A and B) and nuclear translocation (<ce:cross-ref id="crosref0450" refid="fig4">Fig. 4</ce:cross-ref>A), leading to inhibition of its dimerization and its ability to bind DNA in the nucleus (<ce:cross-ref id="crosref0455" refid="fig4">Fig. 4</ce:cross-ref>B). DNA binding is required to trigger STAT3 transcription activity.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.5" view="all">
                        <ce:label>2.2.5</ce:label>
                        <ce:section-title id="sectitle0070">Sensitivity of mutant KRAS or BRAF-expressing cells towards STAT3 inhibition by 7b</ce:section-title>
                        <ce:para id="p0155" view="all">It was recently reported that the survival and chemoresistance of melanoma harboring the BRAF (V600E) mutant could be attributed to enhanced STAT3 activation [<ce:cross-ref id="crosref0460" refid="bib10">10</ce:cross-ref>]. At the same time, a recent report by Gough et al. [<ce:cross-ref id="crosref0465" refid="bib38">38</ce:cross-ref>] investigated the role of STAT3 in a murine K-Ras G12D mutant-dependent hematopoietic neoplasia. Inhibition of STAT3 phosphorylation at S727 by point mutation caused a substantial delay in the onset of the disease. This suggested the importance of mitochondrial STAT3 phosphorylation at S727 as a mediator of K-RAS induced neoplastic hematopoietic cell growth. From these observations, we hypothesized that our new inhibitors might show enhanced cytotoxic activities in cells expressing BRAF or KRAS mutants compared to cells expressing their WT forms.</ce:para>
                        <ce:para id="p0160" view="all">
                           <ce:cross-ref id="crosref0470" refid="fig4">Fig. 4</ce:cross-ref>C shows the effect of <ce:bold>7b</ce:bold> on inhibiting the proliferation of different cancer cell lines including the glioblastoma and breast cancer cell lines (U87-MG and MDA-MB-468 respectively) that express wild type forms of BRAF and KRAS, the pancreatic carcinoma cell line Miapaca-2 and the non-small cell lung cancer cell lines NCI–H157 and A549 that express mutated form of KRAS as well as the BRAF V600E mutant melanoma cell lines A375, 451 Lu and MEL 1617. Interestingly, cells expressing the BRAF-mutant are more sensitive to <ce:bold>7b</ce:bold> compared to cells expressing wild type BRAF and KRAS, as well as mutant KRAS (<ce:cross-ref id="crosref0475" refid="fig4">Fig. 4</ce:cross-ref>C), and in all cases, sensitivity appears to correlate with inhibition of STAT3 phosphorylation at both Y705 and S727 (<ce:cross-refs id="crosrefs0030" refid="fig3 fig7">Fig. 3A, B and 7</ce:cross-refs>A).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.6" view="all">
                        <ce:label>2.2.6</ce:label>
                        <ce:section-title id="sectitle0080">The mechanism of anticancer activity in the BRAF mutant A375 melanoma cell line</ce:section-title>
                        <ce:para id="p0175" view="all">
                           <ce:bold>7b and 7c inhibited A375 cell proliferation -</ce:bold> As the STAT3 pathway regulates cell survival and proliferation [<ce:cross-ref id="crosref0500" refid="bib2">2</ce:cross-ref>,<ce:cross-ref id="crosref0505" refid="bib4">4</ce:cross-ref>], we measured the colony formation of the BRAF<ce:sup loc="post">V600E</ce:sup> mutant A375 melanoma cell line following incubation with different doses of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold>. Dose-dependent suppression of cell proliferation was noted when measured over 10 days (<ce:cross-ref id="crosref0510" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>A).</ce:para>
                        <ce:para id="p0180" view="all">
                           <ce:bold>7b inhibited STAT3 cytokine-induced activation in the A375 melanoma cell line -</ce:bold> Induction of STAT3 activation by cytokines such as IL-6 (interleukin-6) can be abrogated using a STAT3 inhibitor targeting the SH2 domain [<ce:cross-ref id="crosref0515" refid="bib35">35</ce:cross-ref>,<ce:cross-ref id="crosref0520" refid="bib39">39</ce:cross-ref>]. To test this hypothesis in the A375 melanoma cell line, cells were incubated overnight in serum-free media containing different doses of <ce:bold>7b</ce:bold> then induced in full media containing 25 ng/mL IL-6 for 30 min. Cells were then harvested and lysed. The immunoblot shown in <ce:cross-ref id="crosref0525" refid="fig5">Fig. 5</ce:cross-ref>B suggests a dose-dependent inhibition of IL-6-mediated STAT3 activation by <ce:bold>7b</ce:bold> with significant inhibition starting at a concentration of ∼ 5 μM. This was evidenced by suppression of STAT3 Y705 and S727 phosphorylation besides a dose-dependent inhibition of the expression of Cyclin D1, the STAT3 downstream protein.</ce:para>
                        <ce:para id="p0185" view="all">
                           <ce:bold>Reactive oxygen species (ROS) generation in A375 cells treated with different doses of 7b -</ce:bold> STAT3 acts as one of the primary regulators of the antioxidant response that eliminate cytotoxic ROS from the cell. Inhibition of STAT3 activity is expected to cause accumulation of ROS, leading to apoptosis [<ce:cross-ref id="crosref0530" refid="bib35">35</ce:cross-ref>]. ROS generation was detected in A375 cells that were incubated with different doses of <ce:bold>7b</ce:bold> overnight in full media, followed by treatment with 2′,7′-dichloro-fluorescein diacetate (DCFH-DA) for 30 min. The amount of 2′,7′-dichloro-fluorescein that corresponds to the level of ROS in the treated cells was estimated using flow cytometry. <ce:cross-ref id="crosref0535" refid="fig5">Fig. 5</ce:cross-ref>C shows the dose-response generation of ROS in A375 cells treated with different doses of <ce:bold>7b</ce:bold>. This suggests that ROS generation may contribute to cell death.</ce:para>
                        <ce:para id="p0190" view="all">
                           <ce:bold>Cell cycle arrest induction by the new hybrids in A375 cells -</ce:bold> Inhibition of the JAK1/2/STAT3 pathway by a small-molecule inhibitor has been reported to block the cell cycle in the G1 phase [<ce:cross-ref id="crosref0540" refid="bib41">41</ce:cross-ref>]. Cell cycle analysis of A375 cells treated with <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> for 24 h revealed a dose-dependent cell cycle arrest in the G1 phase (<ce:cross-ref id="crosref0545" refid="fig6">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig6"/></ce:float-anchor>A and B). In this experiment, the G0/G1-phase fraction increased from 56.2% (DMSO treated) to 63.0% and 75.4%, at 10 and 25 μM <ce:bold>7b</ce:bold>, respectively, while increased from 55.5% (DMSO treated) to 56.7% and 61.1%, at 10 and 25 μM <ce:bold>7c</ce:bold>, respectively (<ce:cross-ref id="crosref0550" refid="fig6">Fig. 6</ce:cross-ref>A and B). These observations are consistent with dose-response upregulation of p27kip1 expression and downregulation of Cyclin D1 expression that was shown by immunoblotting using cells that have been treated in the same way (<ce:cross-ref id="crosref0555" refid="fig6">Fig. 6</ce:cross-ref>C), suggesting that inhibiting the STAT3 pathway by the new hybrids blocks cell cycle progression.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.7" view="all">
                        <ce:label>2.2.7</ce:label>
                        <ce:section-title id="sectitle0085">The mechanism of anticancer activity in BRAF mutant melanoma with SB-590885-acquired resistance</ce:section-title>
                        <ce:para id="p0195" view="all">Enhanced STAT3 activation has recently been defined as one of the significant drivers of tumor acquired resistance to different treatments. For example, Lee et al. suggested that STAT3 activation promotes Erlotinib resistance in EGFR-mutant lung cancer cells [<ce:cross-ref id="crosref0560" refid="bib42">42</ce:cross-ref>]. Notarangelo et al. reported that STAT3 activation could be the primary regulator of the acquired resistance to a BRAF inhibitor in BRAF-mutant thyroid carcinoma cells [<ce:cross-ref id="crosref0565" refid="bib15">15</ce:cross-ref>]. And it was also reported that activation of STAT3 or overexpression of paired box homeotic gene 3 (PAX3) triggered resistance to vemurafenib in melanoma cell lines harboring the BRAF<ce:sup loc="post">V600E</ce:sup> mutation. PAX3/STAT3 downregulation or STAT3 inhibition by a small molecule suppressed the growth of vemurafenib-resistant melanoma cell lines [<ce:cross-ref id="crosref0570" refid="bib3">3</ce:cross-ref>].</ce:para>
                        <ce:para id="p0200" view="all">In order to investigate the ability of our new hybrids to combat the resistance to BRAF inhibitors in melanoma cell lines harboring the V600E BRAF mutant, we tested the ability of <ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, <ce:bold>7g, 7h</ce:bold> and <ce:bold>7i</ce:bold> to inhibit STAT3 activity and overcome the acquired resistance of two different melanoma cell lines to a BRAF inhibitor. The previously reported [<ce:cross-ref id="crosref0575" refid="bib43">43</ce:cross-ref>] SB-590885-resistant cell lines 451 Lu-R and MEL 1617-R, bearing the BRAF<ce:sup loc="post">V600E</ce:sup> mutant, were obtained by treatment with increasing concentrations of the BRAF inhibitor SB-590885. These resistant cell lines were reported to exhibit cross-resistance to other specific BRAF inhibitors including PLX4720 [<ce:cross-ref id="crosref0580" refid="bib43">43</ce:cross-ref>].</ce:para>
                        <ce:para id="p0205" view="all">
                           <ce:bold>7b and 7c inhibited STAT3/PAX feedback activation in melanoma cell lines resistant to BRAF inhibitor</ce:bold> - To investigate the ability of the compounds to inhibit the STAT3 pathway in resistant melanoma, we examined the effect of the inhibitors on STAT3 phosphorylation and the expression of its downstream target PAX3 in the four melanoma cell lines. Each cell line was treated with two different doses of each inhibitor (10 and 25 μM) for 12 h and the expression levels of STAT3 phosphorylated on Ser727 (Ser-STAT3), Tyr705 (Tyr-STAT3), total STAT3 (STAT3), total PAX3 and actin were determined and compared to a DMSO control. <ce:cross-ref id="crosref0585" refid="fig7">Fig. 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor>A showed the ability of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> to inhibit STAT3 phosphorylation and PAX3 expression in a dose-dependent manner in both SB-590885-sensitive and SB-590885-resistant 451 Lu cell lines, however the less active compounds <ce:bold>7g</ce:bold>, <ce:bold>7h</ce:bold>, and <ce:bold>7i</ce:bold> showed either limited or no ability to inhibit the STAT3 pathway in the cell lines tested (<ce:bold>7h</ce:bold> and <ce:bold>7i</ce:bold> data not shown). This suggests a correlation between the potent anticancer activity of these compounds and their ability to inhibit the STAT3 pathway. Similar effects were observed in SB-590885-sensitive and SB-590885-resistant MEL 1617 cell lines (<ce:cross-ref id="crosref0590" refid="fig7">Fig. 7</ce:cross-ref>A).</ce:para>
                        <ce:para id="p0210" view="all">The inability of <ce:bold>7g</ce:bold>, <ce:bold>7h</ce:bold>, and <ce:bold>7i</ce:bold> to inhibit STAT3 phosphorylation in-cells suggests that their anticancer activities are predominantly due to their ability to release NO. Noticeably, when <ce:bold>7g</ce:bold> loses its ability to donate NO (compare to the corresponding ketone <ce:bold>6g</ce:bold>), it shows no anticancer activity (6g exhibited average growth inhibition of 2% in <ce:cross-ref id="crosref0595" refid="appsec1">Table S1</ce:cross-ref>). The potent activity of <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> can, therefore, be attributed to a combination of STAT3 pathway inhibition and NO production. As expected, <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> showed a similar ability to inhibit the phosphorylation of STAT3 in both SB-590885-sensitive and SB-590885-resistant cell lines, with more potent inhibitory activity towards the phosphorylation of Y705 than S727.</ce:para>
                        <ce:para id="p0215" view="all">
                           <ce:bold>Inhibition of STAT3-dependent luciferase reporter expression in both SB-590885-sensitive and resistant cell lines -</ce:bold> To further examine if <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> are potent STAT3 inhibitors in both SB-590885-sensitive and SB-590885-resistant cell lines, we evaluated their dose-response effect on the activity of a STAT3 promoter, using a dual-luciferase reporter assay. The STAT3 transcription activity in the four cell lines was estimated after the transient transfection of a mixture of an inducible STAT3-responsive firefly luciferase construct and a constitutively active renilla luciferase construct. As shown <ce:cross-ref id="crosref0600" refid="fig8">Fig. 8</ce:cross-ref>A and in the table in <ce:cross-ref id="crosref0605" refid="fig7">Fig. 7</ce:cross-ref>B, <ce:bold>7</ce:bold>
                           <ce:bold>b</ce:bold> and <ce:bold>7c</ce:bold> inhibited STAT3 transcription in both 451-Lu-S and 451 Lu-R cell lines with similar potencies (IC<ce:inf loc="post">50</ce:inf>’s are 6.3 ± 0.7 μM and 4.7 ± 0.8 μM for <ce:bold>7b</ce:bold> and 7.9 ± 1.3 and 17.0 ± 3.0 μM for <ce:bold>7c,</ce:bold> respectively). A comparable effect of the two inhibitors was observed on the other two cell lines (MEL 1617-S and MEL 1617-R), <ce:bold>7b</ce:bold> exhibited IC<ce:inf loc="post">50</ce:inf>’s of 10.3 ± 2.4 and 9.9 ± 1.3 μM, and <ce:bold>7c</ce:bold> showed IC<ce:inf loc="post">50s</ce:inf> of 21.4 ± 4 and 15.6 ± 4 μM, respectively. The control inhibitor <ce:bold>7g</ce:bold> showed a limited ability to inhibit STAT3 transcription in all the cell lines tested (IC<ce:inf loc="post">50</ce:inf>’s in the range of 35–70 μM), suggesting that the sensitivity of the anticancer activity of these inhibitors resides in their ability to both inhibit STAT3 and release NO at the same time. However, we cannot rule out the possibility that the presence of the oxime structure itself is responsible for the enhanced anticancer activity of these STAT3 inhibitors.</ce:para>
                        <ce:para id="p0220" view="all">
                           <ce:bold>The new hybrids inhibited proliferation of melanoma cell lines with acquired resistance to BRAF-inhibition -</ce:bold> We have demonstrated that <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> block STAT3 signal activation in four different cell lines. Consistent with this, STAT3–PAX3 inhibition by <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> resulted in growth inhibition (<ce:cross-ref id="crosref0610" refid="appsec1">Figs. S1 and 7B</ce:cross-ref>) in both SB-590885-resistant and SB-590885-sensitive cell lines. The IC<ce:inf loc="post">50</ce:inf>’s of sensitive cell lines 451 Lu–S and MEL 1617-S were 1.8 and 8.4 μM for <ce:bold>7b</ce:bold>, 11.3, and 46.1 μM for <ce:bold>7c</ce:bold> and 0.06 and 0.08 μM for PLX-4720 respectively. The IC<ce:inf loc="post">50</ce:inf>’s of the resistant 451 Lu-R and MEL 1617-R cell lines that did not exhibit any growth inhibition by PLX-4720 were 7.8 and 10.8 μM for <ce:bold>7b</ce:bold> and 47 and 54 μM for <ce:bold>7c</ce:bold> respectively, which are similar to the IC<ce:inf loc="post">50</ce:inf>’s of inhibition of the sensitive cell lines by the same compounds. This suggests the capability of these inhibitors to overcome the acquired resistance to SB-590885. Noticeably, <ce:bold>7g</ce:bold> did not show any growth inhibition for any tested cell lines up to a concentration of 50 μM.</ce:para>
                        <ce:para id="p0225" view="all">It has been reported that MEL1617-R cells exhibit more resistance to the MEK inhibitor GSK1120212 than MEL1617-S cells. In order to impede ERK phosphorylation, suppress cell viability, and induce G0/G1 cell cycle arrest, 10-fold more of GSK1120212 was required [<ce:cross-ref id="crosref0615" refid="bib43">43</ce:cross-ref>]. Interestingly, comparable cytotoxic effects of the STAT3 inhibitors, <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold>, were observed in both cell lines (<ce:cross-ref id="crosref0620" refid="appsec1">Figs. S1 and 7B</ce:cross-ref>). The similar effect of the inhibitors on STAT3 phosphorylation and transcription activity in the two cell lines (<ce:cross-ref id="crosref0625" refid="fig7">Fig. 7</ce:cross-ref>A and B, and 8A) is consistent with the notion that some BRAF inhibitor-resistant cells lines may exhibit less resistance to STAT3 inhibitors than to MEK inhibitors.</ce:para>
                        <ce:para id="p0230" view="all">We also performed MTS assays to monitor the effect of the inhibitors on cell proliferation at different time points (<ce:cross-ref id="crosref0630" refid="appsec1">Fig. S2</ce:cross-ref>). Each cell line has been incubated with three concentrations of <ce:bold>7b</ce:bold> (DMSO, 1, 5, and 50 μM), and the MTS assay was performed after 24, 48, and 72 h of incubation. The results represented in (<ce:cross-ref id="crosref0635" refid="appsec1">Fig. S2</ce:cross-ref>) indicated that compound <ce:bold>7b</ce:bold> was capable of effectively suppressing 451 Lu–S and R, MEL 1617-S and R cell proliferation in a dose-dependent manner, with comparable effect on both SB-590885 sensitive and resistant cell lines.</ce:para>
                        <ce:para id="p0235" view="all">
                           <ce:bold>7b favorably inhibited resistant melanoma cell survival by apoptosis induction -</ce:bold> Suppressing STAT3 signaling in several cancer cells resulted in growth arrest and apoptosis. To investigate the ability of <ce:bold>7b</ce:bold> to induce apoptosis in SB-590885 sensitive and resistant cell lines, we determined its ability to enhance the formation of cleaved PARP and caspase-7 using western blotting. As shown in <ce:cross-ref id="crosref0640" refid="fig8">Fig. 8</ce:cross-ref>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor>B, <ce:bold>7b</ce:bold> increased the formation of cleaved PARP and caspase-7 levels in both 451 Lu–S and R cell lines in a dose-dependent manner, suggesting the ability of <ce:bold>7b</ce:bold> to induce apoptosis of these cell lines. Furthermore, we established these results using the Caspase 3/7 activity assay using IncuCyte Caspase-3/7 reagent and Incucyte® ZOOM equipment (methods section). As shown in <ce:cross-ref id="crosref0645" refid="fig8">Fig. 8</ce:cross-ref>C, compound <ce:bold>7b</ce:bold> induced caspase activity and apoptosis in 451 Lu resistant cell lines in a dose-dependent manner.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0090">Conclusion</ce:section-title>
                  <ce:para id="p0240" view="all">Here we report the synthesis of several hybrid compounds with an ability to simultaneously inhibit STAT3 signaling and to release NO into cells. <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> showed promising anticancer activity in several cell lines. Direct binding to STAT3 was confirmed using molecular docking studies, and a displacement assay using a FAM-labeled phospho-peptide that binds STAT3 in the SH2 domain. The new hybrids inhibited STAT3 tyrosine phosphorylation in several cancer cell lines. They did not affect the phosphorylation of other STAT isoforms. <ce:bold>7c</ce:bold> inhibited STAT3 nuclear translocation in mouse embryonic fibroblasts and STAT3 DNA binding in the A375 melanoma cell line. The sensitivity of cancer cells carrying BRAF mutations to STAT3 inhibition was confirmed using these new inhibitors. <ce:bold>7b</ce:bold>, and <ce:bold>7c</ce:bold> inhibited STAT3 phosphorylation in A375 cell line after exposure to cytokine (IL-6), induced production of reactive oxygen species and arrested cell growth at the G1 phase. These effects resulted in potent inhibition of A375 colonies formation by <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> in a dose-dependent manner. Moreover, <ce:bold>7b</ce:bold> and <ce:bold>7c</ce:bold> were able to inhibit cellular growth and proliferation and induce apoptosis of SB-590885-sensitive and resistant cell lines with comparable potency. This anticancer activity was attributed to their ability to both inhibit STAT3 transcription and release NO. The compounds discovered in this study may have potential as lead compounds for further development of dual-functional NO-releasing STAT3 inhibitors for treating BRAF-inhibitor resistant melanomas and/or other resistant types of cancer that is susceptible to STAT3 inhibition.</ce:para>
               </ce:section>
               <ce:section id="sec4" role="materials-methods" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0095">Materials and methods</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0100">Chemistry</ce:section-title>
                     <ce:para id="p0245" view="all">Chemicals and solvents are of analytical grade. Melting points were determined on a Stuart electro-thermal melting point apparatus and were uncorrected. IR spectra were performed on Nicolet iS5 (ATR) FT-IR spectrometer at the faculty of pharmacy, Minia University. <ce:sup loc="post">1</ce:sup>H spectra were recorded on Bruker Advance III 400 MHz, faculty of Benisweif University and Burker AG, Switzerland, 500 MHz, faculty of Pharmaceutical Sciences, Umm Al-Qura University, Mecca, Saudi Arabia using TMS as a reference standard and DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> as solvent. Chemical shifts (<ce:italic>δ</ce:italic>) are expressed in parts per million (ppm), and coupling constants (<ce:italic>J</ce:italic>) are expressed in Hertz. The signals are designated as follows: s, singlet; d, doublet; t, triplet; m, multiplet. <ce:sup loc="post">13</ce:sup>C spectra were recorded on Burker AG, Switzerland, 125 MHz, Faculty of Pharmaceutical Sciences, Umm Al-Qura University, Mecca, Saudia Arabia using TMS as a reference standard, and DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> as the solvent. Chemical shifts (<ce:italic>δ</ce:italic>) are expressed in parts per million (ppm). Electron ionization mass spectra were collected in the Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0105">General procedure for the synthesis of compounds <ce:bold>1a-f</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0250" view="all">A mixture of isatin or 5-methoxyisatin (10 mmol), 33% potassium hydroxide (10 mL) in ethanol (20 mL), and appropriate acetophenone derivative (10 mmol) was heated under reflux for 9–18 h. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with water (50 mL) and extracted with ether (3 × 50 mL). The aqueous layer was neutralized with 1 M hydrochloric acid. The formed precipitate was filtered off, washed with water, dried, and crystallized from ethanol.</ce:para>
                        <ce:section id="sec4.1.1.1" view="all">
                           <ce:label>4.1.1.1</ce:label>
                           <ce:section-title id="sectitle0110">2-Phenylquinoline-4-carboxylic acid <ce:bold>(1a)</ce:bold> [<ce:cross-ref id="crosref0650" refid="bib44">44</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0255" view="all">White needles (0.19 g; 80% yield); m.p. 212–214 °C; reported 208–210 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.2" view="all">
                           <ce:label>4.1.1.2</ce:label>
                           <ce:section-title id="sectitle0115">2-(4-Chlorophenyl)quinoline-4-carboxylic acid <ce:bold>(1b)</ce:bold> [<ce:cross-ref id="crosref0655" refid="bib44">44</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0260" view="all">Pale yellow powder (0.24 g; 85% yield); m.p. 144–146 °C; reported 142–144 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.3" view="all">
                           <ce:label>4.1.1.3</ce:label>
                           <ce:section-title id="sectitle0120">2-(4-Methoxyphenyl)quinoline-4-carboxylic acid <ce:bold>(1c)</ce:bold> [<ce:cross-ref id="crosref0660" refid="bib44">44</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0265" view="all">White powder (0.22 g; 72% yield); m.p. 197–198 °C; reported 195–196 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.4" view="all">
                           <ce:label>4.1.1.4</ce:label>
                           <ce:section-title id="sectitle0125">2-(4-Chlorophenyl)-6-methoxyquinoline-4-carboxylic acid <ce:bold>(1d)</ce:bold> [<ce:cross-ref id="crosref0665" refid="bib45">45</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0270" view="all">White powder (0.22 g; 71% yield); m.p. 265–267 °C; reported 264–266 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.5" view="all">
                           <ce:label>4.1.1.5</ce:label>
                           <ce:section-title id="sectitle0130">6-Methoxy-2-(4-methoxyphenyl)quinoline-4-carboxylic acid <ce:bold>(1e)</ce:bold> [<ce:cross-ref id="crosref0670" refid="bib45">45</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0275" view="all">White powder (0.23 g; 75% yield); m.p. 242–244 °C; reported 243–244 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.6" view="all">
                           <ce:label>4.1.1.6</ce:label>
                           <ce:section-title id="sectitle0135">2-(3,4-Dimethoxyphenyl)-6-methoxyquinoline-4-carboxylic acid <ce:bold>(1f)</ce:bold> [<ce:cross-ref id="crosref0675" refid="bib46">46</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0280" view="all">Yellowish white powder (0.23 g; 70% yield); m.p. 230–233 °C; reported 235 °C.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0140">General procedure for the synthesis of compounds <ce:bold>(2a-f)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0285" view="all">A mixture of the appropriate 4-carboxylic acid <ce:bold>1a–f</ce:bold> (10 mmol), absolute ethanol (20 mL), and concentrated sulfuric acid (2 mL) was refluxed for 10 h. The solution was concentrated under reduced pressure; the mixture was allowed to cool at room temperature, diluted with water then rendered alkaline with a sodium bicarbonate solution. The formed precipitate was filtered off, washed with water and crystallized from ethanol.</ce:para>
                        <ce:section id="sec4.1.2.1" view="all">
                           <ce:label>4.1.2.1</ce:label>
                           <ce:section-title id="sectitle0145">Ethyl 2-phenylquinoline-4-carboxylate <ce:bold>(2a)</ce:bold> [<ce:cross-ref id="crosref0680" refid="bib47">47</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0290" view="all">Yellow liquid (0.20g; 75% yield); m.p; reported 51 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.2" view="all">
                           <ce:label>4.1.2.2</ce:label>
                           <ce:section-title id="sectitle0150">Ethyl 2-(4-chlorophenyl)quinoline-4-carboxylate <ce:bold>(2b)</ce:bold> [<ce:cross-ref id="crosref0685" refid="bib48">48</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0295" view="all">White solid (0.24 g; 80% yield); m.p. 79–81 °C; reported 72–73 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.3" view="all">
                           <ce:label>4.1.2.3</ce:label>
                           <ce:section-title id="sectitle0155">Ethyl 2-(4-methoxyphenyl)quinoline-4-carboxylate (2c) [<ce:cross-ref id="crosref0690" refid="bib49">49</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0300" view="all">White solid (0.21 g; 69% yield); m.p. 87–88 °C; reported 86–87 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.4" view="all">
                           <ce:label>4.1.2.4</ce:label>
                           <ce:section-title id="sectitle0160">Ethyl 2-(4-chlorophenyl)-6-methoxyquinoline-4-carboxylate <ce:bold>(2d)</ce:bold> [<ce:cross-ref id="crosref0695" refid="bib45">45</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0305" view="all">White solid (0.28 g; 85% yield); m.p. 129–130 °C; reported 128–129 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.5" view="all">
                           <ce:label>4.1.2.5</ce:label>
                           <ce:section-title id="sectitle0165">Ethyl 6-methoxy-2-(4-methoxyphenyl)quinoline-4-carboxylate <ce:bold>(2e)</ce:bold> [<ce:cross-ref id="crosref0700" refid="bib45">45</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0310" view="all">Yellowish white solid (0.26 g; 79% yield); m.p. 99–101 °C; reported 96–98 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.6" view="all">
                           <ce:label>4.1.2.6</ce:label>
                           <ce:section-title id="sectitle0170">Ethyl 2-(3,4-dimethoxyphenyl)-6-methoxyquinoline-4-carboxylate <ce:bold>(2f)</ce:bold> [<ce:cross-ref id="crosref0705" refid="bib50">50</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0315" view="all">Yellow solid (0.21 g; 59% yield); m.p. 106–108 °C; reported 105–106 °C.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0175">General procedure for the synthesis of compounds <ce:bold>(3a-f)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0320" view="all">To a solution of <ce:bold>2a-f</ce:bold> (10 mmol) in ethanol (20 mL), hydrazine monohydrate (97%, 3 mL) was added and refluxed for 3–7 h. After cooling, the formed precipitate was filtered off, washed with water dried, and crystallized from ethanol.</ce:para>
                        <ce:section id="sec4.1.3.1" view="all">
                           <ce:label>4.1.3.1</ce:label>
                           <ce:section-title id="sectitle0180">2-Phenylquinoline-4-carbohydrazide <ce:bold>(3a)</ce:bold> [<ce:cross-ref id="crosref0710" refid="bib51">51</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0325" view="all">White solid (0.22 g; 84% yield); m.p. 225–226 °C; reported 222 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.2" view="all">
                           <ce:label>4.1.3.2</ce:label>
                           <ce:section-title id="sectitle0185">2-(4-Chlorophenyl)quinoline-4-carbohydrazide <ce:bold>(3b)</ce:bold> [<ce:cross-ref id="crosref0715" refid="bib52">52</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0330" view="all">White solid (0.27 g; 91% yield); m.p. 234–236 °C; reported 235–237 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.3" view="all">
                           <ce:label>4.1.3.3</ce:label>
                           <ce:section-title id="sectitle0190">2-(4-Methoxyphenyl)quinoline-4-carbohydrazide <ce:bold>(3c)</ce:bold> [<ce:cross-ref id="crosref0720" refid="bib52">52</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0335" view="all">White solid (0.25 g; 87% yield); m.p.208–210 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.4" view="all">
                           <ce:label>4.1.3.4</ce:label>
                           <ce:section-title id="sectitle0195">2-(4-Chlorophenyl)-6-methoxyquinoline-4-carbohydrazide <ce:bold>(3d)</ce:bold> [<ce:cross-ref id="crosref0725" refid="bib45">45</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0340" view="all">White solid (0.22 g; 78% yield); m.p. 233–235 °C; reported 233–234 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.5" view="all">
                           <ce:label>4.1.3.5</ce:label>
                           <ce:section-title id="sectitle0200">6-Methoxy-2-(4-methoxyphenyl)quinoline-4-carbohydrazide <ce:bold>(3e)</ce:bold> [<ce:cross-ref id="crosref0730" refid="bib45">45</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0345" view="all">White solid (0.21 g; 66% yield); m.p. 158–160 °C; reported 159–161 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.6" view="all">
                           <ce:label>4.1.3.6</ce:label>
                           <ce:section-title id="sectitle0205">2-(3,4-Dimethoxyphenyl)-6-methoxyquinoline-4-carbohydrazide <ce:bold>(3f)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0350" view="all">White solid (0.19 g; 55% yield); m.p. 223–226 °C; IR (KBr, cm<ce:sup loc="post">−1</ce:sup>): 3360, 3257 (NH, NH<ce:inf loc="post">2</ce:inf>), 1645 (CO); <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.04 (s, 1H, CO–<ce:underline>NH</ce:underline>), 8.06 (s, 1H, Ar–H), 8.02 (d, <ce:italic>J</ce:italic> = 9.2 Hz 1H, Ar–H), 7.87 (s, 1H, Ar–H), 7.83 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar–H), 7.65 (s, 1H, Ar–H), 7.46 (d, <ce:italic>J</ce:italic> = 9.2 Hz, 1H, Ar–H), 7.11 (d, <ce:italic>J</ce:italic> = 8.4 Hz 1H, Ar–H), 4.74 (s, 2H, <ce:underline>NH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.91 (s, 3H, <ce:underline>-OCH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 3.89 (s, 3H,<ce:underline>-OCH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 3.85 (s, 3H, <ce:underline>-OCH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0210">General procedure for the synthesis of compounds <ce:bold>(4a-i</ce:bold>)</ce:section-title>
                        <ce:para id="p0355" view="all">The detailed synthesis and spectral analysis of these intermediates have been previously reported [<ce:cross-ref id="crosref0735" refid="bib53">53</ce:cross-ref>]. In brief, equimolar quantities of the appropriate carbohydrazide <ce:bold>3a-f</ce:bold> (100 mmol) and allyl or phenyl isothiocyanate (100 mmol) in 125 mL of absolute ethanol were heated under reflux for 4 h. The solvent was evaporated under vacuum. Then 100 mL of 2 N NaOH solution was added. The solution was refluxed for 3 h. The reaction mixture was cooled and acidified to pH 2 with concentrated HCl. The formed precipitate was filtered off, washed with water, and recrystallized from ethanol.</ce:para>
                        <ce:section id="sec4.1.4.1" view="all">
                           <ce:label>4.1.4.1</ce:label>
                           <ce:section-title id="sectitle0215">4-Phenyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4a)</ce:bold> [<ce:cross-ref id="crosref0740" refid="bib54">54</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0360" view="all">Orange needles (0.22 g; 60% yield); m.p. 280–281 °C; reported 278–280 °C<ce:bold>.</ce:bold>
                           </ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.2" view="all">
                           <ce:label>4.1.4.2</ce:label>
                           <ce:section-title id="sectitle0220">4-Allyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4b)</ce:bold> [<ce:cross-ref id="crosref0745" refid="bib53">53</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0365" view="all">White solid (0.21 g; 62% yield); m.p. 266–268 °C; reported 266–268 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.3" view="all">
                           <ce:label>4.1.4.3</ce:label>
                           <ce:section-title id="sectitle0225">4-Allyl-5-(2-(4-chlorophenyl)quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4c)</ce:bold> [<ce:cross-ref id="crosref0750" refid="bib53">53</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0370" view="all">Yellow solid (0.28 g; 75% yield); m.p. 182–183 °C; reported 182–183 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.4" view="all">
                           <ce:label>4.1.4.4</ce:label>
                           <ce:section-title id="sectitle0230">5-(2-(4-Chlorophenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4d)</ce:bold> [<ce:cross-ref id="crosref0755" refid="bib53">53</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0375" view="all">White solid (0.29 g; 70% yield); m.p. 198–200 °C; reported 198–200 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.5" view="all">
                           <ce:label>4.1.4.5</ce:label>
                           <ce:section-title id="sectitle0235">5-(2-(4-Methoxyphenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4e)</ce:bold> [<ce:cross-ref id="crosref0760" refid="bib53">53</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0380" view="all">White solid (0.28 g; 69% yield); m.p. 260–266 °C; reported 260–266 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.6" view="all">
                           <ce:label>4.1.4.6</ce:label>
                           <ce:section-title id="sectitle0240">4-Allyl-5-(2-(4-methoxyphenyl)quinolin-4-yl)-4H-1,2,4-triazole-3-thiol <ce:bold>(4f)</ce:bold> [<ce:cross-ref id="crosref0765" refid="bib53">53</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0385" view="all">White solid (0.23 g; 62% yield); m.p. 135–136 °C; reported 135–136 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.7" view="all">
                           <ce:label>4.1.4.7</ce:label>
                           <ce:section-title id="sectitle0245">5-(2-(4-Chlorophenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4g)</ce:bold> [<ce:cross-ref id="crosref0770" refid="bib53">53</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0390" view="all">White solid (0.35 g; 79% yield); m.p. 238–240 °C; reported 238–240 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.8" view="all">
                           <ce:label>4.1.4.8</ce:label>
                           <ce:section-title id="sectitle0250">5-(6-Methoxy-2-(4-methoxyphenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4h)</ce:bold> [<ce:cross-ref id="crosref0775" refid="bib53">53</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0395" view="all">Yellow solid (0.31 g; 71% yield); m.p. 269–271 °C; reported 269–271 °C.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.9" view="all">
                           <ce:label>4.1.4.9</ce:label>
                           <ce:section-title id="sectitle0255">5-(2-(3,4-Dimethoxyphenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazole-3-thiol <ce:bold>(4i)</ce:bold> [<ce:cross-ref id="crosref0780" refid="bib53">53</ce:cross-ref>]</ce:section-title>
                           <ce:para id="p0400" view="all">Yellowish white solid (0.31 g; 66% yield); m.p. 230–231 °C; reported 230–231 °C.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0260">Synthesis of <ce:italic>N</ce:italic>-(4-acetylphenyl)-2-bromoacetamide <ce:bold>(</ce:bold>
                           <ce:bold>5</ce:bold>
                           <ce:bold>)</ce:bold> [<ce:cross-ref id="crosref0785" refid="bib55">55</ce:cross-ref>]</ce:section-title>
                        <ce:para id="p0405" view="all">To a stirred mixture of <ce:italic>p</ce:italic>-aminoacetophenone (0.85 g, 6.3 mmol) in dichloromethane (20 mL) and potassium carbonate (0.17 g, 1.3 mmol) in 100 mL water cooled in an ice bath, bromoacetyl bromide (1.86 g, 9.2 mmol) in 30 mL dichloromethane was added in a drop-wise manner with stirring over 30 min. Stirring was continued for 2 h at 0 <ce:sup loc="post">
                              <ce:bold>°</ce:bold>
                           </ce:sup>C, then at room temperature overnight. The reaction mixture was extracted with dichloromethane (3 × 50 mL), and the organic layer was washed with distilled water (2 × 50 mL), dried over anhydrous sodium sulfate, filtered off, evaporated on a rotary evaporator and the residue was recrystallized from 95% ethanol to give compound <ce:bold>5;</ce:bold> off-white crystals (0.24 g, 95% yield); m.p. 155 °C; reported 157 °C.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.6" view="all">
                        <ce:label>4.1.6</ce:label>
                        <ce:section-title id="sectitle0265">General procedure for the synthesis of compounds <ce:bold>(6a-i)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0410" view="all">An equimolar mixture of <ce:bold>4a-i</ce:bold>, compound <ce:bold>5</ce:bold> (1 mmol), and TEA (0.12 g, 1.2 mmol) in acetonitrile (50 mL) was heated at reflux for 4–8 h. The reaction mixture was evaporated to dryness. The residue was crystallized from aqueous ethanol affording compounds <ce:bold>6a-i</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.6.1" view="all">
                           <ce:label>4.1.6.1</ce:label>
                           <ce:section-title id="sectitle0270">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((4-phenyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6a)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0415" view="all">White solid (0.36 g; 65% yield); m.p. 124–126 °C; IR (KBr, cm<ce:sup loc="post">−1</ce:sup>): 3310 (NH), 1670 (<ce:underline>CO</ce:underline>CH<ce:inf loc="post">3</ce:inf>), 1660 (<ce:underline>CO</ce:underline>NH); <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.79 (s, 1H, NH), 8.13-8.09 (m, 2H, Ar–H), 8.06 (s, 1H, Ar–H), 8.03 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 2H, Ar–H), 7.97 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H, Ar–H), 7.82 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, Ar–H), 7.76 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H, Ar–H), 7.62 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, Ar–H), 7.50-7.48 (m, 5H, Ar–H), 7.48-7.41 (m, 3H, Ar–H), 4.37 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 2.54 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 197.01, 166.61, 155.68, 152.56, 152.32, 148.29, 143.57, 138.24, 133.66, 133.59, 132.47, 131.02, 130.55, 130.49, 130.43, 130.28, 130.07, 129.42, 127.99, 127.81, 127.47, 126.02, 124.99, 120.89, 118.90, 37.45, 26.93; Anal. Calcd. For C<ce:inf loc="post">33</ce:inf>H<ce:inf loc="post">25</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf>S (555.65): C, 71.33; H, 4.53; N, 12.60; Found: C, 71.56; H, 4.61; N, 12.87; EI–MS (ESI) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: calcd. (555.66); Found: (555.20) (M<ce:sup loc="post">+.</ce:sup>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.2" view="all">
                           <ce:label>4.1.6.2</ce:label>
                           <ce:section-title id="sectitle0275">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((4-allyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6b)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0420" view="all">White solid (0.31 g; 60% yield); m.p. 212–214 °C; IR (KBr, cm<ce:sup loc="post">−1</ce:sup>): 3311 (NH), 1681 (<ce:underline>CO</ce:underline>CH<ce:inf loc="post">3</ce:inf>), 1658 (<ce:underline>CO</ce:underline>NH); <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.76 (s, 1H, NH), 8.32-8.29 (m, 3H, Ar–H), 8.20 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar–H), 7.97 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H, Ar–H), 7.89-7.84 (m, 2H, Ar–H), 7.76 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H, Ar–H), 7.63-7.53 (m, 4H, Ar–H), 5.90-5.81 (m, 1H, CH<ce:inf loc="post">2</ce:inf>–<ce:underline>CH</ce:underline>=CH<ce:inf loc="post">2</ce:inf>), 5.11 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>cis</ce:italic>
                              </ce:inf> = 10.4 Hz, 1H, CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.83(d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>trans</ce:italic>
                              </ce:inf> = 17.2 Hz, 1H, CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.66-4.63 (m, 2H, <ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>–CH), 4.33 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 2.50 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 197.14, 168.06, 162.94, 156.93, 153.97, 153.28, 143.26, 138.84, 138.06, 134.17, 131.62, 130.45, 130.18, 130.03, 129.26, 129.02, 128.10, 128.04, 125.26, 120.64, 119.58, 119.16, 118.02, 47.98, 32.93, 27.78; Anal. Calcd. For C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">25</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf>S (519.62): C, 69.34, H, 4.85; N, 13.48; Found: C, 69.18; H, 4.92; N, 13.72.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.3" view="all">
                           <ce:label>4.1.6.3</ce:label>
                           <ce:section-title id="sectitle0280">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((4-allyl-5-(2-(4-chlorophenyl)-quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6c)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0425" view="all">White solid (0.49 g; 89% yield); m.p. 191–192 °C; IR (KBr, cm<ce:sup loc="post">−1</ce:sup>): 3310 (NH), 1667 (<ce:underline>CO</ce:underline>CH<ce:inf loc="post">3</ce:inf>), 1599 (<ce:underline>CO</ce:underline>NH); <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.79 (s, 1H, NH), 8.33 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar–H), 8.31 (s, 1H, Ar–H), 8.20 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, Ar–H), 7.97 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar–H), 7.88 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, Ar–H), 7.84 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, Ar–H), 7.76 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar–H), 7.64 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar–H), 7.63-7.61 (m, 1H, Ar–H), 5.86-5.79 (m, 1H, CH<ce:inf loc="post">2</ce:inf>–<ce:underline>CH</ce:underline>=CH<ce:inf loc="post">2</ce:inf>), 5.10 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>cis</ce:italic>
                              </ce:inf> = 10.5 Hz, 1H, CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.82 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>trans</ce:italic>
                              </ce:inf> = 17.0 Hz, 1H, CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.64-4.63 (m, 2H, <ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>–CH), 4.33 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 2.54 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 197.01, 166.78, 154.90, 152.41, 151.62, 148.41, 143.56, 137.19, 135.48, 134.32, 132.61, 132.49, 131.24, 130.18, 130.06, 129.55, 129.48, 128.31, 125.67, 125.40, 120.08, 118.92, 118.01, 47.18, 38.25, 26.92; Anal. Calcd. For C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">24</ce:inf>ClN<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf>S (554.06): C, 65.03; H, 4.37; N, 12.64; Found: C, 65.28; H, 4.45; N, 12.89; EI–MS (ESI) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: calcd. (554.07); Found: (554.1) (M<ce:sup loc="post">+.</ce:sup>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.4" view="all">
                           <ce:label>4.1.6.4</ce:label>
                           <ce:section-title id="sectitle0285">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(2-(4-chlorophenyl)quinolin-4-yl)-4-phenyl 4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6d)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0430" view="all">White solid (0.52 g; 89% yield); m.p. 295–297 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.80 (s, 1H, NH), 8.11-8.07 (m, 5H, Ar–H), 7.98 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar–H), 7.83-7.81 (m, 1H, Ar–H), 7.77 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H, Ar–H), 7.64-7.62 (m, 3H, Ar–H), 7.59 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H, Ar–H), 7.54-7.42 (m, 3H, Ar–H), 4.38 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 2.55 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 197.01, 166.61, 154.45, 152.59, 152.27, 148.20, 143.58, 137.03, 135.46, 133.92, 133.53, 132.47, 131.16, 130.56, 130.26, 130.08, 130.01, 129.49, 129.21, 128.21, 127.77, 126.01, 125.07, 120.81, 118.90, 37.43, 26.93; Anal. Calcd. For C<ce:inf loc="post">33</ce:inf>H<ce:inf loc="post">24</ce:inf>ClN<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf>S (590.09): C, 67.17; H, 4.10; N, 11.87; Found: C, 67.42; H, 4.17; N, 12.04; EI–MS (ESI) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: calcd. (590.09); Found: (590.10) (M<ce:sup loc="post">+.</ce:sup>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.5" view="all">
                           <ce:label>4.1.6.5</ce:label>
                           <ce:section-title id="sectitle0290">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(2-(4-methoxyphenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6e)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0435" view="all">White solid (0.50 g; 87% yield); m.p. 185–187 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.81 (s, 1H, NH), 8.08-8.06 (m, 3H, Ar–H), 8.04-7.96 (m, 4H, Ar–H), 7.82-7.76 (m, 3H, Ar–H), 7.57 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H, Ar–H), 7.52-7.49 (m, 5H, Ar–H), 7.07 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H, Ar–H), 4.37 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.84 (s, 3H, O–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.55 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 197.01, 166.62, 161.42, 155.37, 152.47, 152.42, 148.30, 143.58, 133.61, 133.49, 132.50, 130.87, 130.69, 130.53, 130.25, 130.05, 129.78, 128.96, 127.80, 127.49, 125.94, 124.68, 120.50, 118.93, 114.82, 55.83, 37.49, 26.91; Anal. Calcd. For C<ce:inf loc="post">34</ce:inf>H<ce:inf loc="post">27</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">3</ce:inf>S (585.68): C, 69.73; H, 4.65; N, 11.96; Found: C, 69.98; H, 4.67; N, 12.28; EI–MS (ESI) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: calcd. (585.68); Found: (585.5) (M<ce:sup loc="post">+.</ce:sup>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.6" view="all">
                           <ce:label>4.1.6.6</ce:label>
                           <ce:section-title id="sectitle0295">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((4-allyl-5-(2-(4-methoxyphenyl)-quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6f)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0440" view="all">White solid (0.45 g; 83% yield); m.p. 214–216 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.79 (s, 1H, NH), 8.27 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H, Ar–H), 8.23 (s, 1H, Ar–H), 8.14 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar–H), 7.97 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H, Ar–H), 7.84 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, Ar–H), 7.80 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar–H), 7.76 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H, Ar–H), 7.57 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, Ar–H), 7.12 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H, Ar–H), 5.88-5.81 (m, 1H, CH<ce:inf loc="post">2</ce:inf>–<ce:underline>CH</ce:underline>=CH<ce:inf loc="post">2</ce:inf>), 5.11 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>cis</ce:italic>
                              </ce:inf> = 10.5 Hz, 1H, -<ce:underline>CH</ce:underline>=CH<ce:inf loc="post">2</ce:inf>), 4.83 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>trans</ce:italic>
                              </ce:inf> = 17.2 Hz, 1H, –CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.62-4.60 (m, 2H, <ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>–CH), 4.33 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.86 (s, 3H, O–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.54 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 197.01, 166.80, 161.47, 155.75, 152.59, 151.52, 148.49, 143.56, 133.92, 132.64, 132.49, 130.98, 130.80, 130.06, 129.95, 129.26, 127.60, 125.59, 124.96, 119.73, 118.92, 117.98, 114.84, 55.84, 47.18, 38.29, 26.92; Anal. Calcd. For C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">27</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">3</ce:inf>S (549.64): C, 67.74; H, 4.95; N, 12.74; Found: C, 68.01; H, 4.88; N, 12.98.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.7" view="all">
                           <ce:label>4.1.6.7</ce:label>
                           <ce:section-title id="sectitle0300">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(2-(4-chlorophenyl)-6-methoxy-quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6g)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0445" view="all">Yellowish white solid (0.55 g; 90% yield); m.p. 224–225 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.57 (s, 1H, NH), 7.95 (s, 1H, ArH), 7.93-7.91 (m, 4H, Ar–H), 7.84 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 7.61 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H, Ar–H), 7.60-7.58 (m, 1H, Ar–H), 7.54-7.51 (m, 2H, Ar–H), 7.45 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H, Ar–H), 7.35 (s, 1H, Ar–H), 7.16 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H, Ar–H), 7.05 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H, Ar–H), 3.99 (s, 2H, <ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>–S), 3.81 (s, 3H, O–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.49 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm) 197.00, 166.65, 162.95, 158.68, 151.92, 144.40, 143.55, 137.19, 134.92, 133.69, 133.29, 131.69, 130.49, 130.27, 130.04, 130.01, 129.39, 128.84, 127.67, 126.26, 123.53, 121.08, 119.64, 118.93, 103.90, 56.20, 37.54, 26.91; Anal. Calcd. For C<ce:inf loc="post">34</ce:inf>H<ce:inf loc="post">26</ce:inf>ClN<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">3</ce:inf>S (620.12): C, 65.85; H, 4.23; N, 11.29; Found: C, 66.08; H, 4.31; N, 11.57.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.8" view="all">
                           <ce:label>4.1.6.8</ce:label>
                           <ce:section-title id="sectitle0305">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(6-methoxy-2-(4-methoxyphenyl)-quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6h)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0450" view="all">Yellowish white solid (0.44 g; 73% yield); m.p. 229–230 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.79 (s, 1H, NH), 7.95-7.93 (m, 6H, Ar–H), 7.75 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H, Ar–H), 7.50-7.38 (m, 9H, Ar–H), 7.04 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H, Ar–H), 4.36 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.85 (s, 3H, O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>) 3.82 (s, 3H, O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.54 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 197.14, 168.06, 164.02, 162.50, 159.48, 159.17, 156.10, 152.74, 143.26, 137.40, 137.19, 131.62, 131.14, 130.69, 130.59, 130.18, 130.07, 128.75, 128.40, 128.01, 121.29, 120.88, 119.58, 114.11, 104.91, 56.04, 32.93, 27.79; Anal. Calcd. For C<ce:inf loc="post">35</ce:inf>H<ce:inf loc="post">29</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">4</ce:inf>S (615.70): C, 68.28; H, 4.75; N, 11.37; Found: C, 68.54; H, 4.87; N, 11.49; EI–MS (ESI) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: calcd. (615.71); Found: (615.1) (M<ce:sup loc="post">+.</ce:sup>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.9" view="all">
                           <ce:label>4.1.6.9</ce:label>
                           <ce:section-title id="sectitle0310">
                              <ce:italic>N</ce:italic>-(4-Acetylphenyl)-2-((5-(2-(3,4-dimethoxyphenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(6i)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0455" view="all">Yellow solid (0.39 g; 62% yield); m.p. 150–151 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.79 (s, 1H, NH), 8.00-7.97 (m, 4H, Ar–H), 7.76 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H, Ar–H), 7.60 (s, 1H, Ar–H), 7.56-7.52 (m, 3H, Ar–H), 7.44-7.41 (m, 5H, Ar–H), 7.06 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H, Ar–H), 4.37 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.86 (s, 6H, O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 3.82 (s, 3H, O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.55 (s, 3H, CO–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 197.01, 166.66, 158.20, 152.99, 152.73, 152.39, 150.77, 149.48, 144.39, 143.55, 133.75, 132.51, 132.00, 131.46, 131.02, 130.49, 130.26, 130.04, 127.70, 125.77, 123.09, 120.91, 120.03, 118.93, 112.27, 110.25, 104.04, 56.12, 56.08, 37.49, 26.91; Anal. Calcd. For C<ce:inf loc="post">36</ce:inf>H<ce:inf loc="post">31</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">5</ce:inf>S (645.73): C, 66.96, H, 4.84, N, 10.85; Found: C, 67.21; H, 4.92; N, 11.07.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.7" view="all">
                        <ce:label>4.1.7</ce:label>
                        <ce:section-title id="sectitle0315">General procedure for the synthesis of compounds <ce:bold>(7a-i)</ce:bold> [<ce:cross-ref id="crosref0790" refid="bib56">56</ce:cross-ref>]</ce:section-title>
                        <ce:para id="p0460" view="all">A mixture of equimolar amounts of the appropriate ketone <ce:bold>6a-i</ce:bold> (1.00 mmol), hydroxylamine hydrochloride (0.35 g, 5.00 mmol) and anhydrous sodium acetate (0.08 g, 1.00 mmol) in absolute ethanol (30 mL) was heated under reflux for 8–12 h then left to cool. The separated solid was filtered off, washed with dil. ammonia solution (10%), dried and crystallized from aqueous ethanol affording the pure novel products <ce:bold>7a-i</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.7.1" view="all">
                           <ce:label>4.1.7.1</ce:label>
                           <ce:section-title id="sectitle0320">
                              <ce:italic>N</ce:italic>-(4-(1-(Hydroxyimino)ethyl)phenyl)-2-((4-phenyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(7a)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0465" view="all">White solid (0.33 g; 59% yield); m.p. 158–160 °C; IR (KBr, cm<ce:sup loc="post">−1</ce:sup>): 3243 (OH, NH), 1660 (<ce:underline>CO</ce:underline>NH); <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.11 (s, 1H, OH), 10.57 (s, 1H, NH), 8.13 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H, Ar–H), 8.10 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H, Ar–H), 8.06 (s, 1H, Ar–H), 7.03 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H, Ar–H), 7.82 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 1H, Ar–H), 7.64-7.60 (m, 4H, Ar–H), 7.51-7.49 (m, 5H, Ar–H), 7.45-7.42 (m, 3H, Ar–H), 4.35 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 2.14 (s, 3H, -<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 166.04, 155.68, 152.87, 152.64, 152.30, 148.30, 139.64, 138.24, 133.68, 133.61, 132.59, 131.01, 130.53, 130.49, 130.27, 130.01, 129.42, 127.99, 127.82, 127.48, 126.60, 126.03, 125.01, 120.89, 119.30, 37.46, 11.85; Anal. Calcd. For C<ce:inf loc="post">33</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf>S (570.66): C, 69.45, H, 4.59; N, 14.73; Found: C, 69.72; H, 4.55; N, 15.01.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.2" view="all">
                           <ce:label>4.1.7.2</ce:label>
                           <ce:section-title id="sectitle0325">2-((4-Allyl-5-(2-phenylquinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)-thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl)acetamide <ce:bold>(7b)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0470" view="all">Yellowish white solid (0.29 g; 55% yield); m.p. 175–178 °C; IR (KBr, cm<ce:sup loc="post">−1</ce:sup>): 3249 (OH, NH), 1658 (<ce:underline>CO</ce:underline>NH); <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.11 (s, 1H, NH), 10.53 (s, 1H, OH), 8.31 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 2H, Ar–H), 8.29 (s, 1H, Ar–H), 8.21 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar–H), 7.88 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 7.85 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar–H), 7.68–7.61 (m, 5H, Ar–H), 7.60–7.53 (m, 3H, Ar–H), 5.88–5.82 (m, 1H, CH<ce:inf loc="post">2</ce:inf>–<ce:underline>CH</ce:underline>=CH<ce:inf loc="post">2</ce:inf>), 5.12 (d, <ce:italic>Jcis</ce:italic> = 10.2 Hz, 1H, CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.83 (d, <ce:italic>Jtrans</ce:italic> = 17.4 Hz, 1H, CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.64 (d, <ce:italic>J</ce:italic> = 3.6 Hz, 2H, <ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>–CH), 4.30 (s, 2H, S–CH<ce:inf loc="post">2</ce:inf>), 2.14 (s, 3H, CH<ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 166.21, 156.10, 152.85, 152.49, 151.62, 148.49, 139.58, 138.39, 134.17, 132.67, 131.09, 130.52, 130.18, 129.53, 129.44, 128.08, 127.78, 126.59, 125.65, 125.32, 120.14, 119.34, 117.96, 47.19, 38.35, 11.85; Anal. Calcd. For C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf>S (534.63): C, 67.40; H, 4.90; N, 15.72; Found: C, 67.65; H, 4.98; N, 16.04.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.3" view="all">
                           <ce:label>4.1.7.3</ce:label>
                           <ce:section-title id="sectitle0330">2-((4-Allyl-5-(2-(4-chlorophenyl)quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl)acetamide <ce:bold>(7c)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0475" view="all">White solid (0.39 g; 70% yield); m.p. 232–234 °C; IR (KBr, cm<ce:sup loc="post">−1</ce:sup>): 3371 (OH, NH), 1557 (<ce:underline>CO</ce:underline>NH); <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.11 (s, 1H, NH), 10.53 (s, 1H, OH), 8.34 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H, Ar–H), 8.32 (s, 1H, Ar–H), 8.20 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar–H), 7.90–7.87 (m, 1H, Ar–H), 7.84 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar–H), 7.65–7.62 (m, 7H, Ar–H), 5.86–5.80 (m, 1H, CH<ce:inf loc="post">2</ce:inf>–<ce:underline>CH</ce:underline>=CH<ce:inf loc="post">2</ce:inf>), 5.10 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>cis</ce:italic>
                              </ce:inf> = 10.2 Hz, 1H, CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.82 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>trans</ce:italic>
                              </ce:inf> = 16.8 Hz, 1H, CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.64 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 2H, <ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>–CH), 4.30 (s, 2H, S–CH<ce:inf loc="post">2</ce:inf>), 2.14 (s, 3H, CH<ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 166.19, 154.90, 152.84, 152.39, 151.65, 148.41, 139.59, 137.20, 135.48, 134.36, 132.63, 131.21, 130.18, 129.54, 129.46, 128.29, 126.59, 125.67, 125.41, 120.08, 119.33, 118.93, 118.01, 47.19, 38.33, 11.85; Anal. Calcd. For C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">25</ce:inf>ClN<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf>S (569.08): C, 63.32; H, 4.43; N, 14.77; Found: C, 63.59; H, 4.40; N, 14.89.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.4" view="all">
                           <ce:label>4.1.7.4</ce:label>
                           <ce:section-title id="sectitle0335">2-((5-(2-(4-Chlorophenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl)acetamide <ce:bold>(7d)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0480" view="all">Off-white solid (0.48 g; 80% yield); m.p. 178–179 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.10 (s, 1H, OH), 10.40 (s, 1H, NH), 8.08 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 8.02–7.98 (m, 2H, Ar–H), 7.90-7.88 (m, 3H, Ar–H), 7.80 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 7.66–7.62 (m, 2H, Ar–H), 7.59–7.54 (m, 3H, Ar–H), 7.47-7.43 (m, 2H, Ar–H), 7.40 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 7.14-7.09 (m, 3H, Ar–H), 4.00 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 2.27 (s, 3H, -<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 168.06, 164.02, 163.36, 159.48, 156.33, 153.99, 138.82, 138.73, 137.40, 135.59, 135.10, 130.41, 130.07, 130.03, 129.69, 129.58, 129.26, 128.75, 128.40, 128.21, 126.44, 125.26, 121.23, 120.64, 119.61, 32.93, 17.67; Anal. Calcd. For C<ce:inf loc="post">33</ce:inf>H<ce:inf loc="post">25</ce:inf>ClN<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf>S (605.11): C, 65.50; H, 4.16; N, 13.89; Found: C, 65.78; H, 4.11; N, 14.08.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.5" view="all">
                           <ce:label>4.1.7.5</ce:label>
                           <ce:section-title id="sectitle0340">
                              <ce:italic>N</ce:italic>-(4-(1-(Hydroxyimino)ethyl)phenyl)-2-((5-(2-(4-methoxy-phenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)acetamide <ce:bold>(7e)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0485" view="all">Yellow solid (0.45 g; 75% yield); m.p. 175–178 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.12 (s, 1H, OH), 10.59 (s, 1H, NH), 8.05 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H, Ar–H), 8.01-7.99 (m, 3H, Ar–H), 7.78 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, Ar–H), 7.66-7.63 (m, 4H, Ar–H), 7.57 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, Ar–H), 7.49 (d, <ce:italic>J</ce:italic> = 5.4 Hz, 2H, Ar–H), 7.44-7.41 (m, 2H, Ar–H), 7.29-7.09 (m, 1H, Ar–H), 7.06 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H, Ar–H), 4.32 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.83 (s, 3H, -O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.13 (s, 3H, -<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 166.08, 161.42, 155.36, 152.96, 152.56, 152.37, 148.17, 139.60, 133.56, 132.59, 130.97, 130.55, 130.24, 130.00, 129.67, 129.01, 128.20, 127.77, 127.56, 126.60, 125.92, 124.65, 120.53, 119.33, 114.83, 55.82, 37.43, 11.86; Anal. Calcd. For C<ce:inf loc="post">34</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf>S (600.69): C, 67.98; H, 4.70; N, 13.99; Found: C, 68.27; H, 4.76; N, 14.32.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.6" view="all">
                           <ce:label>4.1.7.6</ce:label>
                           <ce:section-title id="sectitle0345">2-((4-Allyl-5-(2-(4-methoxyphenyl)quinolin-4-yl)-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl)acetamide <ce:bold>(7f)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0490" view="all">White solid (0.33 g; 59% yield); m.p. 224–226 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.10 (s, 1H, OH), 10.19 (s, 1H, NH), 8.12 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 7.91 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H, Ar–H), 7.86 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 7.82 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H, Ar–H), 7.64 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 7.56 (s, 1H, Ar–H), 7.49 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar–H), 7.44 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H, Ar–H), 7.04 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H, Ar–H), 5.84-5.76 (m, 1H, –CH<ce:inf loc="post">2</ce:inf>-<ce:underline>CH</ce:underline>=CH<ce:inf loc="post">2</ce:inf>), 5.11 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>trans</ce:italic>
                              </ce:inf> = 14.0 Hz, 1H, –CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 5.06 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>cis</ce:italic>
                              </ce:inf> = 11.0 Hz, 1H, –CH=<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 4.55 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 2H, <ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>–CH=CH<ce:inf loc="post">2</ce:inf>), 4.01 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.78 (s, 3H, O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.28 (s, 3H, CN<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 168.06, 162.94, 162.50, 156.93, 156.33, 153.97, 153.29, 138.84, 138.82, 134.17, 131.14, 130.03, 129.26, 128.22, 128.04, 128.01, 126.45, 125.26, 120.64, 119.62, 119.17, 118.03, 114.10, 56.04, 47.98, 32.93, 17.67; Anal. Calcd. For C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf>S (564.66): C, 65.94; H, 5.00; N, 14.88; Found: C, 65.87; H, 4.94; N, 15.03.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.7" view="all">
                           <ce:label>4.1.7.7</ce:label>
                           <ce:section-title id="sectitle0350">2-((5-(2-(4-Chlorophenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)phenyl) acetamide <ce:bold>(7g)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0495" view="all">Yellow solid (0.50 g; 80% yield); m.p. 267–268 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.10 (s, 1H, OH), 10.56 (s, 1H, NH), 8.05-7.99 (m, 3H, Ar–H), 7.75 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.64-7.61 (m, 3H, Ar–H), 7.56 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H, Ar–H), 7.51 (d, <ce:italic>J</ce:italic> = 8.0, 2H, Ar–H), 7.45-7.41 (m, 5H, Ar–H), 7.39 (s, 1H, Ar–H), 4.34 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.86 (s, 3H, -O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.12 (s, 3H, -<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 168.06, 164.02, 159.48, 156.33, 156.10, 152.74, 138.82, 137.40, 135.59, 135.10, 130.69, 130.08, 129.69, 129.58, 128.76, 128.75, 128.40, 128.22, 128.21, 126.44, 121.29, 120.88, 119.62, 104.91, 56.03, 32.93, 17.67; Anal. Calcd. For C<ce:inf loc="post">34</ce:inf>H<ce:inf loc="post">27</ce:inf>ClN<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf>S (635.14): C, 64.30; H, 4.28; N, 13.23; Found: C, 64.56; H, 4.38; N, 13.57.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.8" view="all">
                           <ce:label>4.1.7.8</ce:label>
                           <ce:section-title id="sectitle0355">
                              <ce:italic>N</ce:italic>-(4-(1-(Hydroxyimino)ethyl)phenyl)-2-((5-(6-methoxy-2-(4-methoxy phenyl)quinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)- acetamide <ce:bold>(7h)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0500" view="all">Yellow solid (0.44 g; 71% yield); m.p. 182–185 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.10 (s, 1H, OH), 10.55 (s, 1H, NH), 7.96-7.93 (m, 4H, Ar–H), 7.65-7.61 (m, 4H, Ar–H), 7.51 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H, Ar–H), 7.45-7.38 (m, 5H, Ar–H), 7.04 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H, Ar–H), 4.33 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.84 (s, 3H, -O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 3.82 (s, 3H, -O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2. [<ce:cross-ref id="crosref0795" refid="bib44">44</ce:cross-ref>], 127.70, 126.58, 125.73, 123.16, 120.77, 119.30, 114.74, 103.95, 56.11, 55.77, 37.50, 11.84; Anal. Calcd. For C<ce:inf loc="post">35</ce:inf>H<ce:inf loc="post">30</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">4</ce:inf>S (630.72): C, 66.65; H, 4.79; N, 13.32; Found: C, 66.91; H, 4.86; N, 13.60.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.9" view="all">
                           <ce:label>4.1.7.9</ce:label>
                           <ce:section-title id="sectitle0360">2-((5-(2-(3,4-Dimethoxyphenyl)-6-methoxyquinolin-4-yl)-4-phenyl-4<ce:italic>H</ce:italic>-1,2,4-triazol-3-yl)thio)-<ce:italic>N</ce:italic>-(4-(1-(hydroxyimino)ethyl)- phenyl)acetamide <ce:bold>(7i)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0505" view="all">Yellowish orange solid (0.38 g; 59% yield); m.p. 177–178 °C; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.09 (s, 1H, OH), 10.57 (s, 1H, NH), 7.99 (s, 1H, Ar–H), 7.97 (s, 1H, Ar–H), 7.69-7.63 (m, 5H, Ar–H), 7.56-7.51 (m, 3H, Ar–H), 7.45-7.40 (m, 5H, Ar–H), 7.06 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H, Ar–H), 4.34 (s, 2H, S–<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">2</ce:inf>), 3.85 (s, 6H, O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 3.82 (s, 3H, O<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>), 2.13 (s, 3H, -<ce:underline>CH</ce:underline>
                              <ce:inf loc="post">3</ce:inf>); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 166.09, 158.21, 152.94, 152.85, 152.67, 152.48, 150.78, 149.46, 144.23, 139.62, 133.76, 132.59, 132.14, 131.33, 130.86, 130.48, 130.26, 127.71, 126.58, 125.79, 123.19, 120.96, 120.06, 119.30, 112.23, 110.22, 104.02, 56.12, 56.10, 56.06, 37.46, 11.84; Anal. Calcd. For C<ce:inf loc="post">36</ce:inf>H<ce:inf loc="post">32</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">5</ce:inf>S (660.74): C, 65.44; H, 4.88; N, 12.72; Found: C, 65.70; H, 4.79; N, 12.96.</ce:para>
                        </ce:section>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0365">Biological evaluation</ce:section-title>
                     <ce:para id="p0510" view="all">
                        <ce:bold>Screening of anti-cancer activity-</ce:bold>Anti-cancer activity of some synthesized compounds was evaluated at the National Cancer Institute (NCI) against 60 cell lines of nine different cancer cell types. NCI selected 11 Compounds titled <ce:bold>6a, 6e, 6g</ce:bold> and <ce:bold>7b-i</ce:bold> for <ce:italic>in-vitro</ce:italic> anti-cancer screening. The procedures of the assay are described at (<ce:inter-ref id="intref0015" xlink:href="http://www.dtp.nci.nih.gov" xlink:type="simple">http://www.dtp.nci.nih.gov</ce:inter-ref>). The human cancer cell lines are grown in Roswell Park Memorial Institute medium (RPMI) that contains 5% fetal bovine serum and 2 μM L-glutamine. Cancer cells are inoculated into 96 well microtiter plates in 100 μL at plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. Then microtiter plates are incubated at 37 °C, 5% CO<ce:inf loc="post">2</ce:inf>, 95% air and 100% relative humidity for 24 h prior to the addition of the tested compounds. After 24 h, two plates of each cell line are fixed <ce:italic>in situ</ce:italic> with trichloroacetic acid (TCA). The tested compounds were dissolved in dimethyl sulfoxide (DMSO) and stored in the freezer before use. An aliquot of frozen drug concentrate is diluted to the desired concentration with complete medium containing 50 μg/mL gentamicin. The compounds were added to the microtiter plates followed by incubation for further 48 h at 37 °C, 5% CO<ce:inf loc="post">2</ce:inf>, 95% air and 100% relative humidity. Fixation of cancer cell lines is carried out through gentle addition of 50 μL of cold 50 %w/v TCA (final concentration, 10% TCA) then incubated for 60 min at 4 °C. The plates are washed five times with tap water after getting rid of the supernatant and allowed to dry in air. Sulforhodamine B (SRB) solution (100 μL) at 0.4% w/v in 1% acetic acid is added to each well, and the plates are incubated for 10 min at room temperature. The unbound dye is discarded by washing five times with 1% acetic acid, and the plates are air-dried. While the bound stain is subsequently solubilized in 10 μM trizma base, and the absorbance is recorded on an automated plate reader at <ce:italic>λ</ce:italic>
                        <ce:inf loc="post">max</ce:inf> of 515 nm. The growth percentage is calculated for each of the drug concentrations. Results are expressed as a mean graph of the percent growth of treated cells relative to untreated control as well as to the time zero number of cells.</ce:para>
                     <ce:para id="p0515" view="all">
                        <ce:bold>STAT3 Displacement Assay <ce:italic>-</ce:italic>
                        </ce:bold> Following our previously published protocol [<ce:cross-ref id="crosref0800" refid="bib57">57</ce:cross-ref>], 18 mL of 2 μM GST tagged STAT3 were mixed with 2 mL GST-beads (Amersham) and agitated for 1 h at 4 °C in PBS buffer containing 0.1% β-mercaptoethanol<ce:italic>.</ce:italic> Then the beads were washed 3 times with 20 mL PBS by spinning down at 2500 rpm for 5 min to remove any non-bound STAT3 and re-suspended in 10 ml PBS<ce:italic>.</ce:italic> 100 μL homogeneous solution of STAT3 bound GST-beads were distributed in each well of Millipore MultiScreen<ce:inf loc="post">HTS</ce:inf>, 96-Well Filter Plates (Cat number: MSHVN4B10). 8 wells contained only 100 μL of the buffer were used as a control<ce:italic>.</ce:italic> Different concentrations of each compound were added to the beads with DMSO concentration adjusted to 2.25% in duplicate<ce:italic>.</ce:italic> The plates were shaken on an orbital shaker (60 rpm/min) for 30 min at room temperature after sealing both the upper surface and the base with aluminum seal (AlumaSeal™ CS Films, sigma)<ce:italic>.</ce:italic> 12.5 μM FAM-labeled 5-GpYLPQTV-NH2 peptide was added to every well, and the shaking continues for another 30 min at room temperature<ce:italic>.</ce:italic> The fluorescence background was adjusted using the wells that contain buffer and peptide. The plates have been transferred to MultiScreen<ce:inf loc="post">HTS</ce:inf> Vacuum Manifold, and the resins were washed two times with PBS buffer to remove any unbound labeled peptide and/or compound. Avoid drying the resin during the washing step<ce:italic>.</ce:italic> The resins were re-suspended in 100 μL PBS buffer, and the plates have been sealed very tightly with aluminum seal. The plates have been inverted upside-down, spinet down at 5000 rpm for 10 min until all the resins were settled on the aluminum foil side. The filters were removed then the fluorescence has been measured by a Perkin-Elmer (Waltham, MA) VICTOR3V 1420 multilabel counter plate reader (Excitation filter F485 and emission filter F535)<ce:italic>.</ce:italic> The measured fluorescence (<ce:italic>λ</ce:italic>
                        <ce:inf loc="post">535</ce:inf>) is directly proportional to the bound labeled peptide to STAT3. If the compound displaces the peptide, the fluorescence should decrease. The % displacement has been calculated considering the measured fluorescence in the absence of any compound as 0% displacement.</ce:para>
                     <ce:para id="p0520" view="all">
                        <ce:bold>Cell culture –</ce:bold> A375, 451 Lu–S, and MEL 1617-S melanoma cell lines were cultured in RPMI-1640 medium (Invitrogen) supplemented with 1X Glutamax (Invitrogen). The resistant form of these cell lines (451 Lu-R and MEL 1617-R) were maintained in the same media containing 1 μM of PLX4720. Cells were cultured in a humidified 5% CO2 incubator at 37 °C. For Western blotting, cells were seeded at 800,000–1000,000 cells per well in a 6-well plate and incubated for 24 h before incubation with or without compounds for 12 h. Human non-small cell lung cancer cell line (NCI–H157-ATCC CRL-5802) was provided as a gift from Prof. Jonathan M. Kurie lab, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. (A549-ATCC CCL-185) was purchased from the American type culture collection (ATCC; Manassas, VA) and both were maintained in RPMI-1640 medium. The human pancreas ductal adenocarcinoma cell line (MIA PaCa-2 – ATCC CRL-1420) was purchased from ATCC. Human Glioma cell line (U87-MG-ATCC HTB-14) was obtained from the Neurosurgery Tissue Bank, University of California, San Francisco, USA, and both were maintained DMEM medium. The human breast adenocarcinoma cell line (MCF7-ATCC HTB-22) was purchased from ATCC and (MDA-MB-468 – ATCC HTB-132) was provided as a gift from Prof. Chandra Bartholomeusz lab, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. and both were cultured in DMEM/F12 medium. All media were supplemented with FBS (FBS; 10%; US-Origin, heat-inactivated, Life Technologies), 100 U ml−1 penicillin, and 100 μg ml−1 streptomycin (Life Technologies) and maintained in a 37 °C incubator with 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                     <ce:para id="p0525" view="all">
                        <ce:bold>Western Blotting -</ce:bold> After 12 h of drug incubation, cell lysates were prepared in M-PER ™ Mammalian Protein Extraction Reagent (Thermo-Fisher) after washing in PBS (Invitrogen). The lysates were cleared by centrifugation, and Bradford analysis (Bio-Rad) was used to measure the protein concentration. Lysates containing 60 μg of total protein were fractionated on a 10% SDS polyacrylamide gel (Bio-Rad) and transferred to Hybond-P PVDF Membrane (GE Healthcare). Primary antibodies were incubated overnight at 4 °C using 1: 1,000 antiphospho-Stat3 (Tyr-705), rabbit mAb (Cell Signaling Technology); 1:1000 anti-phospho-Stat3 (Ser727) rabbit polyclonal Ab (Cell Signaling Technology); 1:1000 anti-Stat3 (124H6) mouse mAb (Cell Signaling Technology); 1:1000 anti-PARP (46D11) rabbit mAb (Cell Signaling Technology); 1:1000 anti-cleaved-PARP (D214) rabbit polyclonal Abs (Cell Signaling Technology); 1:1000 anti-Caspase-7 rabbit polyclonal Abs (Cell Signaling Technology); 1:10000 anti-PAX3 (16H22L10) ABfinity rabbit mAb (Invitrogen); 1:1000 anti-Cyclin D1 (DCS6) mouse mAb (Cell Signaling Technology); 1:1000 anti p27 Kip1 (D69C12) XP rabbit mAb (Cell Signaling Technology); 1:1000 anti-phospho-Jak2 (Tyr1007/1008) rabbit antibody (Cell Signaling Technology); 1:1000 anti-Jak2 (D2E12) XP® rabbit mAb (Cell Signaling Technology); 1:1000 anti-Src (L4A1) mouse mAb (Cell Signaling Technology), 1:1000 anti-Phospho-Src Family (Tyr416) rabbit antibody (Cell Signaling Technology); 1:1000 anti-Phospho-Stat1 (Tyr701) (D4A7) rabbit mAb (Cell Signaling Technology); 1:1000 anti-Stat1 (D1K9Y) rabbit mAb (Cell Signaling Technology), 1:1000 anti-Phospho-Stat5 (Tyr694) (D47E7) XP® rabbit mAb (Cell Signaling Technology), 1:1000 anti-Stat5 (D2O6Y) rabbit mAb (Cell Signaling Technology); 1:1000 anti-Phospho-Stat6 (Tyr641) antibody (Cell Signaling Technology); 1:1000 anti-Stat6 (D3H4) rabbit mAb (Cell Signaling Technology); 1/2000 anti-Vinculin (E1E9V) XP rabbit mAb (Cell Signaling Technology) and 1:5000 anti-actin, clone 4 mouse mAb (Millipore). Either anti-rabbit (Bio-Rad) or anti-mouse (Cell Signaling Technology) horseradish peroxidase-conjugated secondary antibodies and Western Bright ECL Western Blotting Reagents (Advansta) were used to develop the blots. All experiments were reproduced in independent experiments. All experiments were performed two times.</ce:para>
                     <ce:para id="p0530" view="all">
                        <ce:bold>STAT3 Reporter Assay -</ce:bold> Cignal STAT3 Reporter (luc) Kit: CCS-9028L was used in this assay according to the manufacturer protocol (<ce:inter-ref id="intref0020" xlink:href="http://www.sabiosciences.com" xlink:type="simple">www.sabiosciences.com</ce:inter-ref>). The Cignal Reporter Assays (luc) include pre-formulated, transfection-ready reporter, negative control, and positive control. Cells were seeded in white (clear bottom) 96-well plate and transfected with a mixture of inducible STAT3-responsive firefly luciferase construct and constitutively expressing Renilla luciferase construct (40:1) using Lipofectamine 3000 reagent (following manufacturer protocol-Invitrogen), after 48 h of transfection, cells were treated with different doses of each inhibitor with vehicle (DMSO) for 12 h. Dual-luciferase assay was performed using Promega dual luciferase assay reagent. The change in the activity of each signaling pathway is determined by comparing the normalized luciferase activities of the reporter in treated versus untreated cells. The identically treated negative control transfectants serve as a specificity control. The positive control serves as a control for transfection efficiency by monitoring GFP expression, as well as a positive control for both the firefly and Renilla luciferase assays.</ce:para>
                     <ce:para id="p0535" view="all">
                        <ce:bold>Cell growth and proliferation assays -</ce:bold> The MTS assay (CellTiter 96® Aqueous One Solution Cell Proliferation Assay from Promega) was used to detect the viability and/or proliferation of cells following the manufacturer protocol. All experiments were performed in triplicate.</ce:para>
                     <ce:para id="p0540" view="all">
                        <ce:bold>ROS production assessment by flow cytometry</ce:bold> - 1 × 10<ce:sup loc="post">6</ce:sup> A375 cells were seeded in 60 mm plate and incubated overnight to settle. Next day cells were treated with either DMSO, 10, or 25 μM <ce:bold>7b</ce:bold> in full RPMI medium for 18 h. Cells were digested with trypsin, and washed three times with PBS and incubated with a final concentration of 10 μM DCFH-DA (2′, 7′-dichlorofluorescein diacetate, ROS-sensitive dye) for 30 min at 37 °C in the dark with a density of 1X10<ce:sup loc="post">6</ce:sup> cells/mL. Cells were washed two times in pre-warmed DPBS before resuspension in DPBS. The fluorescence was detected by flow cytometry (488 nm laser for excitation and detected by 535 nm filter) using BD LSR Fortessa SORP Flow Cytometer. Data were processed using FlowJo v10 (Tree Star, Inc., Ashland, OR, USA) software.</ce:para>
                     <ce:para id="p0545" view="all">
                        <ce:bold>Colony formation assay -</ce:bold> A375 cells were plated (2500 cells per well) in 6-well plate containing RPMI media with 5% FBS. Cells were allowed to settle overnight then treated with different doses of <ce:bold>7b</ce:bold> or <ce:bold>7c</ce:bold>. Cells were allowed to grow for 14 days, then fixed for 15 min in 4% paraformaldehyde and stained with 0.2% crystal violet (in 20% methanol) for 10 min. Cells were washed several times with water before imaging.</ce:para>
                     <ce:para id="p0550" view="all">
                        <ce:bold>Immunofluorescence study –</ce:bold> 2000 MEF (Mouse Embryonic Fibroblast) cells were seeded in each well of a 96-well black plate with clear bottom. Cells were incubated to adhere for 24 h and then incubated with different doses of each inhibitor in serum-free media for another night before induction by full RPMI media containing 100 nM EGF for 30 min. Cells were washed by PBS, fixed by 4% paraformaldehyde in PBS for 10 min at room temperature. The cells were permeabilized with 0.2% Triton X-100 for 5 min and blocked with 10% Goat serum (Cell Signaling Technology). Immunostaining was performed by incubating cells with monoclonal anti-STAT3 antibody produced in mouse (124H6) (Cell signaling Tech), followed by anti-mouse IgG (H+L), F(ab’)2 Fragment (Alexa Fluor®488 Conjugate) (Cell signaling Tech). DAPI (4′,6′-diamidino-2-phenylindole) was included in the mounting medium as a counterstain for nuclei. Cells were visualized and quantified using the Cytation 5 cell imaging system.</ce:para>
                     <ce:para id="p0555" view="all">
                        <ce:bold>IncuCyte single-cell apoptosis analysis -</ce:bold> 2000 451 Lu-R cells were seeded in each well of 96 well plates, cells were left for 24 h to adhere then treated with different doses of <ce:bold>7b</ce:bold> in full media with a constant concentration of the lncuCyte Caspase-3/7 reagent. Cells were incubated and imaged in the lncuCyte® ZOOM equipment with a × 10 objective at different time points. The number of apoptotic cells was normalized to the percentage confluency at the final time point to account for cell proliferation.</ce:para>
                     <ce:para id="p0560" view="all">
                        <ce:bold>Cell Cycle Analysis -</ce:bold> A375 cells were treated with DMSO, 10, or 25 μM of <ce:bold>7b</ce:bold> or <ce:bold>7c</ce:bold> for 24 h in full media. Cells were harvested and washed twice with phosphate-buffered saline (PBS) and fixed in ice-cold 70% ethanol overnight at −20 °C as previously described. The next day, cells were washed two times with PBS and re-suspended in Propidium Iodide (PI)/RNase Staining Solution (cell signaling Cat # 4087) for 30 min at room temperature, light-protected. Cell-cycle analysis was performed using BD LSRFortessa SORP Flow Cytometer. Data obtained from the cell cycle distributions were analyzed using FlowJo v10 (Tree Star, Inc., Ashland, OR, USA) software. FlowJo v10 was employed to estimate the percentage of cells in G1, S, and G2.</ce:para>
                     <ce:para id="p0565" view="all">
                        <ce:bold>Measurement of NO release -</ce:bold> The amount of nitric oxide released was determined using Griess Reagent Kit for Nitrite Determination (Molecular Probes, Eugene, Oregon. kit no. G-7921) [<ce:cross-ref id="crosref0805" refid="bib58">58</ce:cross-ref>]. 280 μL of the nitrite-containing sample (100 μM of each compound in a solution of either phosphate buffer (pH 7.4) or 0.1 N HCl (pH 1), 5 mM DTT and 2% DMSO) were added in each well of a microplate. The mixture was incubated for different time points at room temperature, then 20 μL of Griess Reagent (equal volumes of N-(1-naphthyl)ethylenediamine and sulfanilic acid) was added. After 30 min, the absorbance of the nitrite-containing samples was measured at 548 nm relative to the reference sample that contains 20 μL of Griess Reagent and 280 μL of phosphate buffer (pH 7.4), 2 mM DTT and 1% DMSO. Sodium nitrite solutions were prepared at different concentrations to construct the calibration curve. The amount of NO released (mol/mol) was measured relative to the amount of NO released from standard sodium nitrite solutions.</ce:para>
                     <ce:para id="p0570" view="all">
                        <ce:bold>Nuclear extract preparation and gel shift assays -</ce:bold> A375 cells were seeded in 60 mm plate then treated overnight with different concentrations of <ce:bold>7b</ce:bold>, <ce:bold>7c</ce:bold>, or DMSO in full RPMI media. The cells were harvested, and the nuclear extract was prepared as previously described [<ce:cross-ref id="crosref0810" refid="bib59">59</ce:cross-ref>]. After washing the cells with PBS, cells were suspended in 250 μL low salt lysis buffer containing 10 mM Hepes (pH 8), 10 mM NaCl, 5 mM MgCl2, and 0.5 mM DTT. Cells were incubated in ice for 30 min, nuclei were pelleted by centrifugation at 1200<ce:italic>g</ce:italic> for 4 min, supernatant was discarded and 25 μL of high salt lysis buffer (10 mM Hepes pH 8, 300 mM Kcl, 5 mM MgCl2, 0.5 mM DTT, 20% glycerol) was added to the pellets to extract the nucleus. The tubes were incubated in a rotating wheel for 30 min at 4 °C before centrifugation for 20 min at 11000 g. The protein content of the supernatant was quantified using Bradford reagent, and 5 μg were used for each EMSA reaction. All buffers were supplemented with 1X Complete EDTA-free Protease Inhibitors Cocktail and PhosSTOP Phosphatase Inhibitors Cocktail (Roche Diagnostics). EMSA analysis was carried out using IRDye® 700 STAT3 Consensus Oligonucleotide following the manufacture protocol (Cat. Number 829–07922, LI-COR Biosciences). Stat3 Consensus and Mutant Oligonucleotides were purchased from Santa Cruze Biotechnologies (Cat. numbers # sc-2571 and sc-2572).</ce:para>
                     <ce:para id="p0575" view="all">
                        <ce:bold>Docking Studies -</ce:bold> Docking was carried out with AutoDock 4.2 [<ce:cross-ref id="crosref0815" refid="bib60">60</ce:cross-ref>]. The atomic coordinate of the STAT3-SH2 domain (res586-688) (PDB ID: <ce:inter-ref id="intref0025" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) [<ce:cross-ref id="crosref0820" refid="bib28">28</ce:cross-ref>] was used as the receptor model for docking. Docking was carried out centered at Gln635 with a grid box of 100 × 100 × 100 points in three dimensions with a spacing of 0.375 Å. The charges of proteins were assigned using the PDB2PQR [<ce:cross-ref id="crosref0825" refid="bib61">61</ce:cross-ref>] server, and electrostatic potential was calculated using APBS [<ce:cross-ref id="crosref0830" refid="bib62">62</ce:cross-ref>]. The electrostatic potential varied from −5<ce:italic>K</ce:italic>
                        <ce:inf loc="post">B</ce:inf>
                        <ce:italic>T</ce:italic>/<ce:italic>e</ce:italic> to +5<ce:italic>K</ce:italic>
                        <ce:inf loc="post">B</ce:inf>
                        <ce:italic>T</ce:italic>/<ce:italic>e</ce:italic> and was depicted using Chimera [<ce:cross-ref id="crosref0835" refid="bib63">63</ce:cross-ref>] in panels A and B from red to blue, respectively.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0370">Declaration of competing interest</ce:section-title>
               <ce:para id="p0580" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0375">Acknowledgment</ce:section-title>
               <ce:para id="p0585" view="all">This research has been supported by the <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100012533" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Faculty of Pharmacy, Minia University, Minia, Egypt</ce:grant-sponsor>, the <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/100000928" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Welch Foundation, USA</ce:grant-sponsor> grant <ce:grant-number refid="gs3">F-1390</ce:grant-number> (to K.N.D.) and <ce:grant-sponsor id="gs5" sponsor-id="https://doi.org/10.13039/100004917" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Cancer Prevention and Research Institute of Texas, USA</ce:grant-sponsor> grant <ce:grant-number refid="gs5">RP140649</ce:grant-number> (to K.N.D.). The authors would like to thank Prof. Kenneth Tsai, H. Lee Moffitt Cancer Center & Research Institute, Florida, USA, for providing the four tested melanoma cell lines.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0380">Supplementary data</ce:section-title>
                  <ce:para id="p0590" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Manuscript supplementary materials</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Manuscript supplementary materials</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523419310372/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0385">Supplementary data</ce:section-title>
                  <ce:para id="p0595" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0030" xlink:href="https://doi.org/10.1016/j.ejmech.2019.111885" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2019.111885</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0390">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Chabner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biological basis for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Intern. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>1993</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>633</sb:first-page>
                              <sb:last-page>637</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">Chabner, B. A, Biological basis for cancer treatment. Ann Intern Med 1993, 118 (8), 633-637.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Russo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Torrisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Bevelacqua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Perrotta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Libra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>McCubrey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Spandidos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Stivala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Malaponte</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Melanoma: molecular pathogenesis and emerging target therapies (Review)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1481</sb:first-page>
                              <sb:last-page>1489</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">Russo, A. E.; Torrisi, E.; Bevelacqua, Y.; Perrotta, R.; Libra, M.; McCubrey, J. A.; Spandidos, D. A.; Stivala, F.; Malaponte, G., Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 2009, 34 (6), 1481-1489.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sullivan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ryu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Investig. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>133</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2041</sb:first-page>
                              <sb:last-page>2049</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">Liu, F.; Cao, J.; Wu, J.; Sullivan, K.; Shen, J.; Ryu, B.; Xu, Z.; Wei, W.; Cui, R., Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol 2013, 133 (8), 2041-2049.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Furtek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Backos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Matheson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Reigan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strategies and approaches of targeting STAT3 for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>308</sb:first-page>
                              <sb:last-page>318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">Furtek, S.L.; Backos, D.S.; Matheson, C.J.; Reigan, P, Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol 2016, 11 (2), 308-318.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factor STAT3 as a novel molecular target for cancer prevention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>926</sb:first-page>
                              <sb:last-page>957</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">Xiong, A.; Yang, Z.; Shen, Y.; Zhou, J.; Shen, Q., Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel) 2014, 6 (2), 926-957.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>241</sb:first-page>
                              <sb:last-page>250</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">Wen, Z.; Zhong, Z.; Darnell, J. E., Jr., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82 (2), 241-250.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Heller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Catlett-Falcone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Coppola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jaroszeski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Dalton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5059</sb:first-page>
                              <sb:last-page>5063</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">Niu, G.; Heller, R.; Catlett-Falcone, R.; Coppola, D.; Jaroszeski, M.; Dalton, W.; Jove, R.; Yu, H., Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999, 59 (20), 5059-5063.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting STAT3 affects melanoma on multiple fronts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Metastasis Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>315</sb:first-page>
                              <sb:last-page>327</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">Kortylewski, M.; Jove, R.; Yu, H., Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005, 24 (2), 315-327.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.X.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ali-Osman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sawaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3550</sb:first-page>
                              <sb:last-page>3560</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Xie, T. X.; Wei, D.; Liu, M.; Gao, A. C.; Ali-Osman, F.; Sawaya, R.; Huang, S., Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23 (20), 3550-3560.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Boyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mijatov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Gowrishankar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Snoyman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Pupo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Scolyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Mann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Kefford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Rizos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1158</sb:first-page>
                              <sb:last-page>1166</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">Becker, T. M.; Boyd, S. C.; Mijatov, B.; Gowrishankar, K.; Snoyman, S.; Pupo, G. M.; Scolyer, R. A.; Mann, G. J.; Kefford, R. F.; Zhang, X. D.; Rizos, H., Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene 2014, 33 (9), 1158-1166.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Chapman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hauschild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Robert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Haanen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ascierto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Larkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dummer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Garbe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Testori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Maio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hogg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lorigan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lebbe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jouary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Schadendorf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ribas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>O’Day</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Sosman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Kirkwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Eggermont</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Dreno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nolop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Nelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Flaherty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>McArthur</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>364</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>26</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2507</sb:first-page>
                              <sb:last-page>2516</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O’Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364 (26), 2507-2516.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Flaherty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Infante</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Daud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gonzalez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Kefford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sosman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Hamid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Schuchter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cebon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ibrahim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kudchadkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Burris</ce:surname>
                                 <ce:suffix>3rd</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Falchook</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Algazi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.V.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Puzanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lebowitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Little</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Allred</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ouellet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Weber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Combined BRAF</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>MEK Inhibition in Melanoma with BRAF V600 Mutations</ce:surname>
                              </sb:author>
                           </sb:authors>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>367</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>18</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1694</sb:first-page>
                              <sb:last-page>1703</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">Flaherty, K. T.; Infante, J. R.; Daud, A.; Gonzalez, R.; Kefford, R. F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; Kudchadkar, R.; Burris, H. A., 3rd; Falchook, G.; Algazi, A.; Lewis, K.; Long, G. V.; Puzanov, I.; Lebowitz, P.; Singh, A.; Little, S.; Sun, P.; Allred, A.; Ouellet, D.; Kim, K. B.; Patel, K.; Weber, J., Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med 2012.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Flaherty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Puzanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ribas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>McArthur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Sosman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>O’Dwyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Grippo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nolop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Chapman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of mutated, activated BRAF in metastatic melanoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>363</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>809</sb:first-page>
                              <sb:last-page>819</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; O’Dwyer, P. J.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. B., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363 (9), 809-819.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.V.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Trefzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Kefford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Ascierto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Chapman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Puzanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hauschild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Robert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Algazi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mortier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Tawbi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wilhelm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Switzky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Swann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.-M.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guckert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Goodman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Streit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Kirkwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Schadendorf</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1087</sb:first-page>
                              <sb:last-page>1095</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">Long, G. V.; Trefzer, U.; Davies, M. A.; Kefford, R. F.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Algazi, A.; Mortier, L.; Tawbi, H.; Wilhelm, T.; Zimmer, L.; Switzky, J.; Swann, S.; Martin, A.-M.; Guckert, M.; Goodman, V.; Streit, M.; Kirkwood, J. M.; Schadendorf, D., Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet Oncology 2012, 13 (11), 1087-1095.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Notarangelo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Sisinni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Trino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Calice</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Simeon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Landriscina</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>433</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>147</sb:first-page>
                              <sb:last-page>155</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">Notarangelo, T.; Sisinni, L.; Trino, S.; Calice, G.; Simeon, V.; Landriscina, M., IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. Cancer Lett 2018, 433, 147-155.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bernard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Nikolovska-Coleska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>89</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Chen, J.; Bai, L.; Bernard, D.; Nikolovska-Coleska, Z.; Gomez, C.; Zhang, J.; Yi, H.; Wang, S., Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. ACS Med Chem Lett 2010, 1 (2), 85-89.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ramesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Birtwistle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Kaluarachchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Bast</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3549</sb:first-page>
                              <sb:last-page>3563</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">Mandal, P. K.; Gao, F.; Lu, Z.; Ren, Z.; Ramesh, R.; Birtwistle, J. S.; Kaluarachchi, K. K.; Chen, X.; Bast, R. C., Jr.; Liao, W. S.; McMurray, J. S., Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem 2011, 54 (10), 3549-3563.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Miyoshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Takaishi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nakajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ikeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tarutani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Iiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Asao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>DiGiovanni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Investig. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>108</sb:first-page>
                              <sb:last-page>117</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">Miyoshi, K.; Takaishi, M.; Nakajima, K.; Ikeda, M.; Kanda, T.; Tarutani, M.; Iiyama, T.; Asao, N.; DiGiovanni, J.; Sano, S., Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 2011, 131 (1), 108-117.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.L.A.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Hirpara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pervaiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Eu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sethi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Do STAT3 inhibitors have potential in the future for cancer therapy?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Investig. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>883</sb:first-page>
                              <sb:last-page>887</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">Wong, A. L. A.; Hirpara, J. L.; Pervaiz, S.; Eu, J. Q.; Sethi, G.; Goh, B. C., Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investig Drugs 2017, 26 (8), 883-887.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>13</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4700</sb:first-page>
                              <sb:last-page>4705</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">Song, H.; Wang, R.; Wang, S.; Lin, J., A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 2005, 102 (13), 4700-4705.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.J.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.W.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11</sb:first-page>
                              <sb:last-page>19</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">Duan, Y. C.; Ma, Y. C.; Zhang, E.; Shi, X. J.; Wang, M. M.; Ye, X. W.; Liu, H. M., Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents. Eur J Med Chem 2013, 62, 11-19.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Becerril</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Benitez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Juarez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Banales</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Zeron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Navarro</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evaluation of the effect of 1,3-bis(4-phenyl)-1H-1,2,3-Triazolyl-2-Propanolol on gene expression levels of JAK2-STAT3, NF-kappaB, and SOCS3 in cells cultured from biopsies of mammary lesions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11–12</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>291</sb:first-page>
                              <sb:last-page>300</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">Becerril, J. L.; Benitez, J. G.; Juarez, J. J.; Banales, J. M.; Zeron, H. M.; Navarro, M. D., Evaluation of the Effect of 1,3-Bis(4-Phenyl)-1H-1,2,3-Triazolyl-2-Propanolol on Gene Expression Levels of JAK2-STAT3, NF-kappaB, and SOCS3 in Cells Cultured from Biopsies of Mammary Lesions. Biochem Genet 2015, 53 (11-12), 291-300.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.P.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Lv</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.X.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5948</sb:first-page>
                              <sb:last-page>5954</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">Hou, Y. P.; Sun, J.; Pang, Z. H.; Lv, P. C.; Li, D. D.; Yan, L.; Zhang, H. J.; Zheng, E. X.; Zhao, J.; Zhu, H. L., Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors. Bioorg Med Chem 2011, 19 (20), 5948-5954.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Yoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.K.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Mukai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Kang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>21</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5036</sb:first-page>
                              <sb:last-page>5046</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Lee, S. M.; Yoon, K. B.; Lee, H. J.; Kim, J.; Chung, Y. K.; Cho, W. J.; Mukai, C.; Choi, S.; Kang, K. W.; Han, S. Y.; Ko, H.; Kim, Y. C., The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3. Bioorg Med Chem 2016, 24 (21), 5036-5046.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nitric oxide donor-based cancer therapy: advances and prospects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>18</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7617</sb:first-page>
                              <sb:last-page>7635</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">Huang, Z.; Fu, J.; Zhang, Y, Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. J Med Chem 2017, 60 (18), 7617-7635.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>507</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">Chen, H.; Yang, Z.; Ding, C.; Chu, L.; Zhang, Y.; Terry, K.; Liu, H.; Shen, Q.; Zhou, J., Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur J Med Chem 2013, 62, 498-507.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Masuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Uehara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Muroya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yokotagawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Furuya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Okawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Otsuka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ogo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ashizawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Oshita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Akiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of a new series of STAT3 inhibitors by virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>371</sb:first-page>
                              <sb:last-page>375</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">Matsuno, K.; Masuda, Y.; Uehara, Y.; Sato, H.; Muroya, A.; Takahashi, O.; Yokotagawa, T.; Furuya, T.; Okawara, T.; Otsuka, M.; Ogo, N.; Ashizawa, T.; Oshita, C.; Tai, S.; Ishii, H.; Akiyama, Y.; Asai, A, Identification of a New Series of STAT3 Inhibitors by Virtual Screening. ACS Med Chem Lett 2010, 1 (8), 371-375.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Groner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Three-dimensional structure of the Stat3beta homodimer bound to DNA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>394</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6689</sb:issue-nr>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>145</sb:first-page>
                              <sb:last-page>151</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Becker, S.; Groner, B.; Muller, C. W, Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998, 394 (6689), 145-151.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Trott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>455</sb:first-page>
                              <sb:last-page>461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">Trott, O.; Olson, A. J., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010, 31 (2), 455-461.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Ridnour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Isenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Flores-Santana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Switzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Donzelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Hussain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Vecoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Paolocci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ambs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Colton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Wink</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The chemical biology of nitric oxide: implications in cellular signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Free Radic. Biol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>18</sb:first-page>
                              <sb:last-page>31</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">Thomas, D. D.; Ridnour, L. A.; Isenberg, J. S.; Flores-Santana, W.; Switzer, C. H.; Donzelli, S.; Hussain, P.; Vecoli, C.; Paolocci, N.; Ambs, S.; Colton, C. A.; Harris, C. C.; Roberts, D. D.; Wink, D. A., The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 2008, 45 (1), 18-31.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pireddu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Urlam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Guida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1922</sb:first-page>
                              <sb:last-page>1933</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Zhang, X.; Sun, Y.; Pireddu, R.; Yang, H.; Urlam, M. K.; Lawrence, H. R.; Guida, W. C.; Lawrence, N. J.; Sebti, S. M, A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res 2013, 73 (6), 1922-1933.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Scuto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Polychronopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Magiatis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Skaltsounis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>6-Bromoindirubin-3’-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>71</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3972</sb:first-page>
                              <sb:last-page>3979</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">Liu, L.; Nam, S.; Tian, Y.; Yang, F.; Wu, J.; Wang, Y.; Scuto, A.; Polychronopoulos, P.; Magiatis, P.; Skaltsounis, L.; Jove, R., 6-Bromoindirubin-3’-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res 2011, 71 (11), 3972-3979.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2718</sb:first-page>
                              <sb:last-page>2731</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">Yu, W.; Li, C.; Zhang, W.; Xia, Y.; Li, S.; Lin, J. Y.; Yu, K.; Liu, M.; Yang, L.; Luo, J.; Chen, Y.; Sun, H.; Kong, L., Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking. J Med Chem 2017, 60 (7), 2718-2731.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Bartolowits</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Pedley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Harvey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Wendt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.J.</ce:given-name>
                                 <ce:surname>Davisson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective inhibition of STAT3 phosphorylation using a nuclear-targeted kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2371</sb:first-page>
                              <sb:last-page>2378</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Bartolowits, M. D.; Brown, W.; Ali, R.; Pedley, A. M.; Chen, Q.; Harvey, K. E.; Wendt, M. K.; Davisson, V. J., Selective Inhibition of STAT3 Phosphorylation Using a Nuclear-Targeted Kinase Inhibitor. ACS Chem Biol 2017, 12 (9), 2371-2378.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>151</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>752</sb:first-page>
                              <sb:last-page>764</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">Guo, J.; Yu, W.; Cai, G.; Zhang, W.; Li, S.; Zhu, J.; Song, D.; Kong, L., Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors. Eur J Med Chem 2018, 151, 752-764.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>An</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Sang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ju</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>162</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>543</sb:first-page>
                              <sb:last-page>554</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">Li, C.; Chen, C.; An, Q.; Yang, T.; Sang, Z.; Yang, Y.; Ju, Y.; Tong, A.; Luo, Y., A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3). Eur J Med Chem 2019, 162, 543-554.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>157</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>887</sb:first-page>
                              <sb:last-page>897</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">Huang, W.; Liu, Y.; Wang, J.; Yuan, X.; Jin, H. W.; Zhang, L. R.; Zhang, J. T.; Liu, Z. M.; Cui, J. R, Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. Eur J Med Chem 2018, 157, 887-897.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Gough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.J.</ce:given-name>
                                 <ce:surname>Marie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lobry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Aifantis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>124</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>14</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2252</sb:first-page>
                              <sb:last-page>2261</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">Gough, D. J.; Marie, I. J.; Lobry, C.; Aifantis, I.; Levy, D. E., STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. Blood 2014, 124 (14), 2252-2261.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Timofeeva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gaponenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Lockett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Tarasov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Michejda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.O.</ce:given-name>
                                 <ce:surname>Perantoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.I.</ce:given-name>
                                 <ce:surname>Tarasova</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>799</sb:first-page>
                              <sb:last-page>809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">Timofeeva, O. A.; Gaponenko, V.; Lockett, S. J.; Tarasov, S. G.; Jiang, S.; Michejda, C. J.; Perantoni, A. O.; Tarasova, N. I., Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol 2007, 2 (12), 799-809.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.V.</ce:given-name>
                                 <ce:surname>Watson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Chambers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A pragmatic approach to the analysis of DNA histograms with a definable G1 peak</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytometry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>1987</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>8</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">Watson, J.V.; Chambers, S.H.; Smith, P.J., A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry 1987, 8 (1), 1-8.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.G.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Q.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.C.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neoplasia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>287</sb:first-page>
                              <sb:last-page>297</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">Xiong, H.; Zhang, Z. G.; Tian, X. Q.; Sun, D. F.; Liang, Q. C.; Zhang, Y. J.; Lu, R.; Chen, Y. X.; Fang, J. Y., Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008, 10 (3), 287-297.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Settleman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>207</sb:first-page>
                              <sb:last-page>221</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">Lee, H. J.; Zhuang, G.; Cao, Y.; Du, P.; Kim, H. J.; Settleman, J., Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26 (2), 207-221.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Kaoud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.D.</ce:given-name>
                                 <ce:surname>Ebelt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Piserchio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zamora-Olivares</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.X.</ce:given-name>
                                 <ce:surname>Van Ravenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Pridgen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Edupuganti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sammons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Warthaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Harger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.J.</ce:given-name>
                                 <ce:surname>Tavares</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Radwan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.V.</ce:given-name>
                                 <ce:surname>Anslyn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.Y.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ghose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Dalby</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature Communications</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5232</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41467-019-12996-8</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">Villanueva, J.; Vultur, A.; Lee, J. T.; Somasundaram, R.; Fukunaga-Kalabis, M.; Cipolla, A. K.; Wubbenhorst, B.; Xu, X.; Gimotty, P. A.; Kee, D.; Santiago-Walker, A. E.; Letrero, R.; D’Andrea, K.; Pushparajan, A.; Hayden, J. E.; Brown, K. D.; Laquerre, S.; McArthur, G. A.; Sosman, J. A.; Nathanson, K. L.; Herlyn, M., Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18 (6), 683-695.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Muscia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Carnevale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bollini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Asís</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Microwave-assisted döbner synthesis of 2-phenylquinoline-4-carboxylic acids and their antiparasitic activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Heterocycl. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>611</sb:first-page>
                              <sb:last-page>614</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">Muscia, G. C.; Carnevale, J. P.; Bollini, M.; Asis, S. E., Microwave-assisted dobner synthesis of 2-phenylquinoline-4-carboxylic acids and their antiparasitic activities. Journal of Heterocyclic Chemistry 2008, 45 (2), 611-614.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>El-Feky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Abd El-Samii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Osman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lashine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Kamel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Thabet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, molecular docking and anti-inflammatory screening of novel quinoline incorporated pyrazole derivatives using the Pfitzinger reaction II</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>104</sb:first-page>
                              <sb:last-page>116</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">El-Feky, S. A; Abd El-Samii, Z. K.; Osman, N. A.; Lashine, J.; Kamel, M. A.; Thabet, H., Synthesis, molecular docking and anti-inflammatory screening of novel quinoline incorporated pyrazole derivatives using the Pfitzinger reaction II. Bioorg Chem 2015, 58, 104-116.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Trikojus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Derivatives of 2-phenyl quinoline, Part I. Preparation of some "atophans" from ventric aldehyde</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Proc. R. Soc. N. S. W.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>1932</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>273</sb:first-page>
                              <sb:last-page>278</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">Trikojus, V. M.; White, D. E., Derivatives of 2-phenyl quinoline, Part I. Preparation of some "atophans" from ventric aldehyde. Journal and Proceedings of the Royal Society of New South Wales 1932, 66, 273-278.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.-h.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-x.</ce:given-name>
                                 <ce:surname>Xi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.-j.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.-h.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-z.</ce:given-name>
                                 <ce:surname>Zeng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, characterization, and DNA-binding properties of copper(II), cobalt(II), and nickel(II) complexes with salicylaldehyde 2-phenylquinoline-4-carboylhydrazone</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Transit. Met. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>267</sb:first-page>
                              <sb:last-page>273</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">Xu, Z.-h.; Xi, P.-x.; Chen, F.-j.; Liu, X.-h.; Zeng, Z.-z., Synthesis, characterization, and DNA-binding properties of copper(II), cobalt(II), and nickel(II) complexes with salicylaldehyde 2-phenylquinoline-4-carboylhydrazone. Transition Metal Chemistry 2008, 33 (2), 267-273.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Leardini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.F.</ce:given-name>
                                 <ce:surname>Pedulli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tundo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zanardi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aromatic annelation by reaction of arylimidoyl radicals with alkynes: a new synthesis of quinolines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Soc., Chem. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>1984</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1320</sb:first-page>
                              <sb:last-page>1321</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">Leardini, R.; Pedulli, G. F.; Tundo, A.; Zanardi, G., Aromatic annelation by reaction of arylimidoyl radicals with alkynes: a new synthesis of quinolines. Journal of the Chemical Society, Chemical Communications 1984, (20), 1320-1321.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.N.</ce:given-name>
                                 <ce:surname>Zemtsova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Zimichev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.L.</ce:given-name>
                                 <ce:surname>Trakhtenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.N.</ce:given-name>
                                 <ce:surname>Klimochkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.V.</ce:given-name>
                                 <ce:surname>Leonova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Balakhnin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.I.</ce:given-name>
                                 <ce:surname>Bormotov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Serova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Belanov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and antiviral activity of several quinoline derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharm. Chem. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>267</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">Zemtsova, M. N.; Zimichev, A. V.; Trakhtenberg, P. L.; Klimochkin, Y. N.; Leonova, M. V.; Balakhnin, S. M.; Bormotov, N. I.; Serova, O. A.; Belanov, E. F., Synthesis and antiviral activity of several quinoline derivatives. Pharmaceutical Chemistry Journal 2011, 45 (5), 267.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.W.</ce:given-name>
                                 <ce:surname>Raulfs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Quinoline-4-carboxylic acid derivatives and their use as color formers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. Pat. Appl.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>1990</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>EP 384313 A1 19900829</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0270">Raulfs, F. W.; Mayer, U., Quinoline-4-carboxylic acid derivatives and their use as color formers. Eur. Pat. Appl 1990, EP 384313 A1 19900829.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.X.</ce:given-name>
                                 <ce:surname>Xi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Z.</ce:given-name>
                                 <ce:surname>Zeng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, characterization, and DNA-binding of Ln(III) complexes with 2-hydroxybenzylidene-2-phenylquinoline-4-carbonylhydrazone</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Coord. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>13</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2193</sb:first-page>
                              <sb:last-page>2202</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">Xu, Z. H.; Xi, P. X.; Chen, F. J.; Zeng, Z. Z., Synthesis, characterization, and DNA-binding of Ln(III) complexes with 2-hydroxybenzylidene-2-phenylquinoline-4-carbonylhydrazone. Journal of Coordination Chemistry 2009, 62 (13), 2193-2202.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Metwally</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Abdel-Aziz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Lashine el</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Husseiny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>Badawy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>24</sb:issue-nr>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8675</sb:first-page>
                              <sb:last-page>8682</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">Metwally, K. A.; Abdel-Aziz, L. M; Lashine el, S. M.; Husseiny, M. I.; Badawy, R. H., Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents. Bioorg Med Chem 2006, 14 (24), 8675-8682.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Mohassab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Abdelhamid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abdel-Aziz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Dalby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Kaoud</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>242</sb:first-page>
                              <sb:last-page>259</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">Mohassab, A. M.; Hassan, H. A.; Abdelhamid, D.; Abdel-Aziz, M.; Dalby, K. N.; Kaoud, T. S., Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations. Bioorg Chem 2017, 75, 242-259.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.A.A.</ce:given-name>
                                 <ce:surname>El-Aal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.I.</ce:given-name>
                                 <ce:surname>El-Emary</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficient synthesis, characterization and biological evaluation of some new atophan carbohydrazide derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>90</sb:first-page>
                              <sb:last-page>99</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">El-Aal, H. A. A.; El-Emary, T. I., Efficient synthesis, characterization and biological evaluation of some new atophan carbohydrazide derivatives Journal of Chemical and Pharmaceutical Research 2014, 6 (12), 90-99.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Savinov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Dey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.D.</ce:given-name>
                                 <ce:surname>Kwong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wyatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                                 <ce:suffix>3rd</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.A.</ce:given-name>
                                 <ce:surname>Hendrickson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>50</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4898</sb:first-page>
                              <sb:last-page>4908</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">Xie, H.; Ng, D.; Savinov, S. N.; Dey, B.; Kwong, P. D.; Wyatt, R.; Smith, A. B., 3rd; Hendrickson, W. A., Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus. J Med Chem 2007, 50 (20), 4898-4908.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Abd-Ellah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abdel-Aziz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Shoman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Beshr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Kaoud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Ahmed</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel 1,3,4-oxadiazole/oxime hybrids: synthesis, docking studies and investigation of anti-inflammatory, ulcerogenic liability and analgesic activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>63</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">Abd-Ellah, H. S.; Abdel-Aziz, M.; Shoman, M. E.; Beshr, E. A.; Kaoud, T. S.; Ahmed, A. F., Novel 1,3,4-oxadiazole/oxime hybrids: Synthesis, docking studies and investigation of anti-inflammatory, ulcerogenic liability and analgesic activities. Bioorg Chem 2016, 69, 48-63.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Kaoud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mitra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Tseng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Taliaferro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tuohetahuntila</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Devkota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sammons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Dalby</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>From in silico discovery to intra-cellular activity: targeting JNK-protein interactions with small molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>721</sb:first-page>
                              <sb:last-page>725</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">Kaoud, T. S.; Yan, C.; Mitra, S.; Tseng, C. C.; Jose, J.; Taliaferro, J. M.; Tuohetahuntila, M.; Devkota, A.; Sammons, R.; Park, J.; Park, H.; Shi, Y.; Hong, J.; Ren, P.; Dalby, K. N., From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules. ACS Med Chem Lett 2012, 3 (9), 721-725.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Broderick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Measurement of nitric oxide production in biological systems by using griess reaction assay</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sensors</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>276</sb:first-page>
                              <sb:last-page>284</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">Sun, J.; Zhang, X.; Broderick, M.; Fein, H, Measurement of Nitric Oxide Production in Biological Systems by Using Griess Reaction Assay. Sensors 2003, 3 (8), 276-284.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sancisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gandolfi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Ambrosetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ciarrocchi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Histone deacetylase inhibitors repress tumoral expression of the proinvasive factor RUNX2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1868</sb:first-page>
                              <sb:last-page>1882</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">Sancisi, V.; Gandolfi, G.; Ambrosetti, D. C.; Ciarrocchi, A., Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2. Cancer Research 2015, 75 (9), 1868-1882.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Morris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Huey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lindstrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Sanner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Belew</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Goodsell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>16</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2785</sb:first-page>
                              <sb:last-page>2791</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J., AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009, 30 (16), 2785-2791.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Dolinsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Nielsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>McCammon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Web Server issue</sb:issue-nr>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>W665</sb:first-page>
                              <sb:last-page>W667</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">Dolinsky, T. J.; Nielsen, J. E.; McCammon, J. A.; Baker, N. A., PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res 2004, 32 (Web Server issue), W665-W667.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sept</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Joseph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Holst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>McCammon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Electrostatics of nanosystems: application to microtubules and the ribosome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>18</sb:issue-nr>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10037</sb:first-page>
                              <sb:last-page>10041</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">Baker, N. A.; Sept, D.; Joseph, S.; Holst, M. J.; McCammon, J. A., Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A 2001, 98 (18), 10037-10041.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Pettersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Goddard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Couch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Greenblatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Ferrin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>UCSF</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chimera–a visualization system for exploratory research and analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>13</sb:issue-nr>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1605</sb:first-page>
                              <sb:last-page>1612</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E., UCSF Chimera-a visualization system for exploratory research and analysis. Journal of computational chemistry 2004, 25 (13), 1605-1612.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>